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ABSTRACT 
Spinal Cord Injury (SCI) is a debilitating condition which causes neurological 
damage and can result in paralysis. SCI results in immediate mechanical damage to the 
spinal cord, but secondary injuries due to inflammation, oxidative damage, and activated 
biochemical pathways leading to apoptosis exacerbate the injury. The only currently 
available treatment, methylprednisolone, is controversial because there is no convincing 
data to support its therapeutic efficacy for SCI treatment 
1
. Because of its inability to 
show marked improvement in SCI patients, methylprednisolone does not have approval 
from the FDA, and remains classified as an optional treatment for SCI. In the absence of 
an effective SCI treatment option, 17β-estradiol has gained significant attention for its 
anti-oxidant, anti-inflammatory, and anti-apoptotic abilities, all events associated with 
secondary SCI. When applied to SCI animal models for treatment, significant functional 
recovery has been reported. Sadly, estradiol is prothrombotic and leads to 
thromboembolic events which are exacerbated in the individuals with SCI due to their 
lack of mobility. This effect has been shown clinically in adult males taking high dose 
estrogens for prostate cancer treatment 
2
. However, thromboembolism has not been 
reported when low estrogen doses are used for treatment. These systemic adverse effects 
preclude the use of free estrogen even for local administration due to short drug half-life 
in the body. 
Biodegradable nanoparticles can be used to increase half-life after local 
administration and to bestow sustained release. Sustained release using PEGylated 
iii 
 
biodegradable polymeric nanoparticles constructed from poly(lactic-co-glycolic acid) 
(PLGA) will endow a consistent, low, but effective dose to be delivered locally. This will 
limit systemic effects due to local administration and low dose, sustained release. PLGA 
was chosen because it has been used extensively for sustained release, and has a record of 
safety in humans 
3
. Hydrophilic polymers can be attached to the carrier to limit protein 
adsorption and prevent uptake by the reticuloendothelial system (RES) or immune system 
4-6
.  
Here, we propose to develop PEGylated nanoparticles loaded with 17β-estradiol 
for treatment of secondary SCI. We will formulate biodegradable poly (lactic-co-
glycolic) acid (PLGA) nanoparticles surface modified with PEG groups to prevent uptake 
and to provide sustained release of the drug at the injury site. We will evaluate the 
performance of the nanoparticle and determine the best dosage for effective treatment of 
SCI. Our ultimate hypothesis is that local administration and sustained release of the drug 
endowed by the nanocarrier will enhance treatment efficacy. The main goal is to 
characterize the nanoparticle delivery system in vitro and in appropriate cell models to 
determine the range of effective doses for application to an animal model. 
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CHAPTER ONE 
INTRODUCTION 
 This document describes the graduate work in the department of Bioengineering 
at Clemson University for the past four years which has focused on nanomaterials and 
their application to solve medical problems. The research aim has been to use 
nanotechnology, specifically surface modified nanoparticles and liposomes, to carry 
pharmaceuticals which suffer from rapid clearance and adverse side effects, and release 
them in low, therapeutically relevant levels only at the site where they are needed.  
 Specifically,  this work focuses on the application of nanobiotechnology for the 
treatment of spinal cord injury to prevent secondary damage which follows the primary 
insult. To best treat this disease, the researchers endeavored to develop a drug delivery 
system that could be administered locally and release a slow, consistent dose of an 
estrogenic drug to the injured tissue. To achieve this goal of local, sustained drug release 
biodegradable nanoparticles were used which were constructed from biocompatible, FDA 
approved polymers. 
 The second chapter of this document includes a detailed review of the relevant 
literature to supply the reader with an understanding of the foundation upon which this 
work is built. This includes a discussion of spinal cord injury and the events that 
accompany and cause much of the damage associated with this type of injury. The third 
chapter discusses the innovation and significance of the work and discusses the specific 
aims which were developed to evaluate the proposed treatment. 
2 
 
 The formulation development and characterization of the nanoparticle delivery 
system is described in chapter four. This includes a discussion of the experiments 
designed to determine the loading efficiency of the estrogenic drug into the polymeric 
particle, analyze different poly (ethylene glycol) (PEG) contents to maximize this loading 
efficiency, and the evaluation of the size and stability of the formulation. This chapter 
also includes an in vitro release method to analyze the release of hydrophobic small 
molecule drugs. This method utilizes albumin, a ubiquitous protein in the bloodstream, 
whose function is the transport of such molecules. In using the protein as an active 
transport system in a dialysis based filtering system, the release profile is more closely 
related to that which would be seen in the body because the same protein transport 
system is present in both cases. The details describing this method and the possible 
applications are outlined in the chapter. 
 The first in vitro cell culture model used to evaluate the efficacy of the developed 
nanoparticle drug delivery system is described in chapter five. This includes the 
experiments necessary to determine the neuroprotective effect of 17β-Estradiol in a 
neuroblastoma model. This is done by quantifying the viability of cells protected by 
estrogen in induced injury-like events. Here, the author illustrates that the treatment 
effectively protects the neuroblastoma cells and that the nanoparticle delivery system is 
an improvement for delivery over DMSO for in vitro cell culture models. Also shown is a 
dose dependence study to determine which dose most effectively protects cells. Also 
evaluated is the best pre-treatment time for effective treatment. The biodegradable 
nanoparticle system will have a lag time before there is release because the drug is 
3 
 
released as the particle degrades. The neuroblastoma cell model is limited in its ability to 
provide dosage information that is translatable to an in vivo animal study because it is a 
cancer cell line. This means that it is more resilient than many nervous system cells, and 
the  studies described herein show that it was not as responsive to estrogens as was 
expected. This led to the exploration of a primary cell model that would be a more 
effective model to translate this treatment into animal models. 
 The sixth chapter describes the primary model used to evaluate the estrogen 
delivery system. Dorsal Root Ganglion neurons were harvested from chicken embryos 
and challenged by SCI-like events. Treatment groups were exposed to estrogen delivered 
by the nanoparticle formulation to determine dose dependence in a similar manner to that 
done for the neuroblastoma cell line. Pre-treatment time was also performed as was done 
for the neuroblastoma model. This model dictates the doses and pre-treatment times that 
will be used to start the animal studies to evaluate the drug efficacy. 
 Overall conclusions of the studies and an examination of the potential future work 
related to this work are included in chapter seven. First, the implications and possible 
applications of the work are summarized. Second, there is a discussion of work to be 
done to carry this technology towards practical applications. The application of the 
described technology to treat those who suffer from spinal cord injury is the major goal 
of this project and the first few steps taken to reach this goal are summarized herein. 
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CHAPTER TWO 
LITERATURE REVIEW 
There is a large emphasis on healthcare and improving the quality of life in the 
United States. The amount of money spent on healthcare soared to 17.3% of the Gross 
Domestic Product, or 2.5 trillion dollars, in 2009 and continues to the rise according to 
USA Today 
7
. According to the same article, 246 billion dollars of this total was spent on 
prescription drugs. These Figures illustrate the demand for modern healthcare which is 
largely met by the development of effective pharmaceuticals. 
However, many of these pharmaceuticals have limitations. One major limitation 
of many drugs is a low circulation time, which is one of the causes of low drug 
concentrations at the disease site 
8,9
 Often, high doses are given to achieve high enough 
concentrations at the disease site. Despite these high doses, only a fraction of the drug 
arrives at the desired location and low concentration of drug at a diseased site prevents 
high levels of efficacy 
10
. In addition, side effects plague many patients, cancer 
chemotherapeutic drugs are one notable example, and high doses only aggravate this 
problem 
11, 12
.  
This limited circulation time and low therapeutic concentrations at the disease site 
occur because the human body is effective at removing foreign molecules, including 
drugs, which results in a short time for the drug to perform its therapeutic action. Most 
therapeutics that utilize the circulatory system for drug delivery see the vast majority of 
the drug cleared from the body in just a few hours 
8
. These are just a few of the 
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limitations of modern medications, others exist, many of which are specific to each 
individual drug. 
 The limitations listed can be addressed, to a certain degree, by the modern 
advances of nanotechnology 
13, 14
. Nanotechnology has gained global attention for its 
unique ability to hurdle some of the barriers that have limited application and innovation 
of many potentially effective therapeutics. The application of nanotechnology to drug 
delivery has seen dramatic success in this area. As will be discussed in this review, 
liposomes and nanoparticles as drug delivery systems have answered many of the 
common drug limitations. Some of the earliest nanomedicine research was dedicated to 
delivering small molecules to a target site with as much specificity and as long a 
circulation lifetime as possible 
4, 5, 15
. A renewed excitement for drug delivery by 
liposomes and nanoparticles was seen in the past two decades as a formulation for each 
has achieved FDA approval 
16-21
. A barrage of research to improve these approved 
delivery devices began and still continues with attempts to actively target and increase 
efficacy 
22, 23
.  
There has been a significant amount of research done on liposomes and 
nanoparticles as pharmaceutical carriers for a variety of small molecule and protein 
drugs. Small molecules, proteins, and enzymes have been used both as targeting moieties 
and for their therapeutic potential 
24-28
. High specificity and rapid reaction rates make 
proteins and enzymes excellent candidates for therapeutic treatment, but some limitations 
exist 
29-31
. Many of these limitations can be addressed by a nanotechnology based 
delivery system that has been thoroughly characterized and evaluated for efficacy with 
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minimal toxicity and side effects. Such a system can provide a medium for delivery, 
stabilization of the drugs, and enable site specific accumulation of drugs. All of which 
make for a more effective treatment. Overcoming these limitations to effective medical 
treatment could increase the development of new treatments and improve the efficacy of 
existing therapies. In addressing these barriers, nanomedicines have the potential to 
revolutionize the pharmaceutical industry and improve healthcare worldwide. 
2.1. Spinal Cord Injury 
Spinal cord injury is a debilitating condition for many which causes neurological 
damage and can result in paralysis. There are an estimated 265,000 people are living in 
the United States with SCI in 2010, with approximately 12,000 new cases each year 
32
. 
The main causes of spinal cord injury are illustrated in Figure 1. The estimated lifetime 
costs for individuals of age 25 and 50 when afflicted with SCI are $1,461,255 and 
$1,031,394, respectively, for incomplete motor function loss at any level. The risk and 
cost escalates as the severity of injury increases.  
 
 
Figure 1: Breakdown of the etiology of spinal cord injuries since 2005 
32
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2.1.1. Primary Injury 
 The primary injury originates with a mechanical insult. Common causes for a 
mechanical insult with enough force to cause physical disruption of the spinal cord are 
shown in Figure 1. Immediately, there is damage to the structural components of the 
spinal cord (Figure 2), as well as damage to the vasculature and to the spinal cord cell 
population 
33
. Axonal disruption also occurs upon the mechanical insult and often 
hemorrhage follows the injury. Despite the extensive damage that can be caused by 
primary injury, because of the unpredictable nature of such injuries, there is little that can 
be done to prevent these injuries. However, secondary effects which follow the primary 
injury can lead to exacerbation of injury and further motor loss can potentially be treated 
34, 35
. 
 
Figure 2: Graphical representation of a spinal cord injury
36
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2.1.2. Secondary Events 
Secondary damage is of primary concern here because much of the neurological 
damage in SCI is caused after the initial trauma or primary insult. This secondary injury 
involves many different harmful pathways including a local inflammatory response,  
 
Table 1: A comparison and contrast between primary and secondary injury 
 
PRIMARY INJURY 
 
SECONDARY INJURY 
Occurs upon mechanical insult 
which initiates the injury. 
Occurs after the initial injury, and is 
mediated by biochemical events after 
primary injury 
Cell death and local damage caused 
by localized mechanical force. 
Caused by a several different factors 
induced at the injury site, but is caused by 
signals and reactions, instead of 
mechanical force. 
No treatments to prevent this type of 
damage, only to promote healing. 
Drugs can be used to prevent or alleviate 
the effects of events which cause exacerbate 
SCI 
Not preventable and cannot be 
treated prior to injury 
Secondary injury is treatable and some of 
the resulting damage can be diminished or 
prevented  
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production of free radicals and reactive oxygen species (ROS),ischemia/reperfusion, 
glutamate excitotoxicity, ionic changes, and the activation of pro-apoptotic proteases 
37
.  
At least a few of these pathways are linked in etiology. In order to understand the best 
treatment methods for this condition, it is vital to understand the damaging pathways 
which lead to neurological damage and potential paralysis. 
After the primary spinal cord injury, migration of neutrophils and macrophages 
(or microglia, as macrophages are called in the central nervous system (CNS)) to the 
damaged site occurs 
38
. These cells are characteristic of inflammation and are 
instrumental in the local cleanup necessitated by the injury. However, these cells release 
ROS that cause oxidative damage in the local tissue 
38
. In addition, ischemia and 
reperfusion also increase local free radical concentrations which cause oxidative damage 
and exacerbate the injury 
39
. 
Another deleterious pathway begins with the up-regulation of an amino acid 
signaling molecule, glutamate, during secondary SCI events 
40
. Glutamate receptors on 
the surface of neuronal cells regulate the intracellular ionic balance. NMDA receptor is a 
specific glutamate receptor which responds to glutamate as well as to its namesake, N-
methyl-D-aspartate (NMDA). This receptor has been incriminated in the pathology of 
secondary SCI because it activates pathways directly involved in apoptotic cell death 
40
. 
NMDA receptors, and some other glutamate receptors, regulate calcium ion ([Ca
2+
]) 
influx into the nervous system cells. An increase in intracellular [Ca
2+
] is also potentially 
mediated by mitochondrial damage caused by SCI which affects the activity Na
+
-K
+
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Figure 3: The biochemical progression of secondary injury following the 
primary insult which initiates the cascade of events. 
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ATPase leading to imbalance in Na
+
-Ca
2+ 
exchange 
41
. This rise in [Ca
2+
] leads to 
protease activation, among activation of other deleterious pathways. Calpain is a calcium 
dependent protease activated in this process. Calpain is always present and plays a role, 
but in higher concentrations, as is seen in secondary SCI due to the local biochemical 
dysfunction, it can initiate a pathway fatal to nervous system cells by degrading 
cytoskeletal and membrane proteins 
42
. The proteolytic activity performed disturbs the 
local environment and leads to apoptosis of CNS cells 
42
. Calpain is an upstream 
regulator of Bax and Caspase-3, both which are implicated in apoptotic cell death. Thus, 
it is vital for a potential therapeutic to have the ability to regulate the response initiated by 
glutamate if a therapy is to be effective in treating secondary SCI. 
2.1.3. Timing of Spinal Cord Injury Events 
The timing of these events following SCI is critical to the development of an 
effective treatment and is outlined by Norenberg et al
43
. Immediately after injury for the 
first 1-2 hours there is little sign of secondary events except for some change in the 
vasculature. Swelling, hemorrhage, and inflammation follow in the acute phase of injury. 
Swelling is present from approximately 3 hours to 3 days after the injury. Inflammation 
also occurs with neutrophils invading the site at about one day, reaching a maximum at 2 
days and retreating almost completely by 3 days. Some hemorrhaging occurs alongside 
these events, but is usually not significant in a typical SCI. Neuronal cells are particularly 
susceptible to death by necrosis or apoptosis in the first few days following injury, and 
demyelination is characteristic during this time period as well. The intermediate stage 
follows from a few days to several weeks. This stage is characterized by revascularization 
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of the injury site and microglia present in the site working to clean up the injury site. Late 
phase healing results in scar formation and final remodeling of the injury site.  Because 
the acute stage is pivotal in the healing process and there are many positive and negative 
events that can occur during this stage, the first few days are critical for surgical 
intervention and treatment with a few weeks after injury still seeing many of the 
secondary effects taking their toll at the injury site. 
We would then expect secondary events to play a role in preventing the recovery, 
or even decrease the neurological state of an individual with a SCI. A study by Gorio et al 
showed that there was essentially no neurological recovery for 72 hours in a rat model 
treated with saline. The rats started with an average mean motor score of 1.2 (on a rating 
scale of 1-7, increasing as motor skills improved), which decreased in the first 12 hours  
 
Figure 4: Methylprednisolone is the current standard of care for SCI 
patients. It resembles Prednisone in chemical structure. 
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and showed almost no recovery up to 72 hours
44
. There have been many studies that have 
shown that intervention within 72 hours has shown a significant increase in functional 
recovery 
45
. This indicates again that immediate treatment to alleviate secondary injury is 
vital to achieve the highest level of neurological recovery. 
2.2. Current Treatments for Spinal Cord Injury 
The current treatment for individuals with SCI is Methylprednisolone (MP). MP 
is a glucocorticoid similar to prednisone in structure. The use of MP is very controversial  
because a contingency of experts consider its therapeutic effects to be questionable at 
best 
41
. Many physicians regard MP as a drug with insufficient proof of its efficacy as a 
SCI therapy 
1
. These opinions are based on clinical results from three studies performed 
in the National Acute Spinal Cord Injury Study (NASCIS) which did not show an 
improvement in the primary outcome of patients treated with MP 
46-48
. As a result, MP is 
concluded to be “an inappropriate standard of care” by Hurlbert and many other 
physicians 
1, 49
. 
The referenced NASCIS I, II, and III results did not show improvement in the 
primary outcome, but a post-hoc analysis determined that early administration (eight 
hours after injury or before) resulted in a functional improvement. Based on this analysis, 
MP quickly became a popularly used treatment for SCI. Since the adoption of MP for 
SCI treatment as a standard of care, the post hoc analysis performed on the NASCIS data 
has come under considerable fire for statistical analysis, randomization, and clinical end 
points 
46,50-52
. Another critical review of the analysis notes that the placebo control group 
treated before 8 hours did not do well, not only when evaluated against the MP treated, 
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but also against the post 8 hour placebo 
53
. This indicates that there may have been a 
problem with the control group, which could dramatically improve the statistical 
significance of the clinical study. Thus, for some reasons mentioned here along with 
others not mentioned (see relevant literature 
1, 41, 49, 52, 53
), there is considerable 
controversy around the use of MP for treatment of SCI. The present study is designed to 
present a novel, delivered therapeutic to effectively treat SCI. 
There are several other treatment methods that are being explored for their 
neuroprotective abilities in the absence of a strong treatment option. One potential 
treatment option is minocycline, an antibiotic that also has shown some success against 
secondary events such as inflammation and apoptosis. Another experimental treatment 
option is fullerenols, which are carbon based nanostructures which act as free radical 
scavengers and interact with glutamate receptors and impart a similar neuroprotective 
affect to estrogens 
54
. There are many other therapies that have also been investigated 
including bone marrow stromal cells, erythropoietin, and glutamate receptor antagonists 
involved in the pathology of SCI
55, 56
. 
Several groups who published animal studies using minocycline as a 
neuroprotectant in traumatic SCI did show that locomotion scores (BBB method) did 
improve under the therapy 
57, 58
. A study initiated by the NIH to verify the result of these 
studies was unable to replicate the level of success achieved previously 
59
. The results of 
a phase II clinical trial into minocycline for spinal cord injury treatment were published 
earlier this year and indicated no significant difference between the treated and a placebo 
60
. There was an indication that there was a therapeutic effect, but significance was not 
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reached for any group. Overall improvement was slightly higher than the placebo, but, 
again, was not significant.  
Erythropoietin is a cytokine that is involved heavily in the erythrocyte life cycle. 
It has also been shown to be involved in the development of the nervous system 
61
. After 
SCI, it is released in response, at least in part, to hypoxic conditions and prevents 
apoptosis and inflammation. It has been examined in SCI animal models as a potential 
treatment and has seen success 
61, 62
. However, there remain concerns due to an increased 
risk of thrombosis after repeated treatments 
63
. 
The major downside to most new treatments, such as fullerenols, is that they are 
unknown and have not been thoroughly evaluated for safety. This lack of approval 
necessitates extensive clinical trials to prove safety and efficacy. Few treatment options 
have been explored as extensively as estrogens for treatment of SCI and estrogens have 
the distinct advantage of having already been approved in many different forms (i.e. birth 
control, menopausal relief treatment options). Some of these forms of estrogens have 
been used for over 60 years and are familiar drugs which have already attained approval. 
In addition they have shown the ability to effectively alleviate many of the secondary 
injury events following SCI. 
2.3. Estrogens for Treatment of Spinal Cord Injury 
As illustrated herein, there are many deleterious pathways involved in the 
pathology of SCI. For this reason, it may be necessary to use several treatments to 
effectively treat SCI, or use a single treatment which plays multiple therapeutic roles 
37
. 
One promising candidate as a multi-acting agent against SCI is 17β-estradiol. This  
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Figure 5: 17β-Estradiol is a hormone that is capable of playing several roles 
in the therapy of SCI. 
estrogen is a steroid hormone that has been studied extensively for its therapeutic 
potential, much of which is not due to its estrogenic properties 
64. 17β-estradiol has been 
shown to have a threefold effect when used in SCI. First, it has been shown to be a potent 
anti-oxidant, thus alleviating the oxidative stress brought on by inflammation, 
ischemia/reperfusion, and the accompanying ROS 
64
. Second, this estrogen has exhibited 
anti-inflammatory activity. This anti-inflammatory action is not anti-oxidant in nature, 
but inhibits microglial activation at the injury site and limits the release of cytokines, 
ROS, free radicals, and complement proteins 
65
. Finally, and perhaps most importantly, 
17β-estradiol is anti-apoptotic. As mentioned previously, SCI initiates many pathways 
which can lead to apoptosis. This estrogen inhibits glutamate induced apoptosis indicated 
previously 
40, 41
. This estrogen has also seen success when applied to in vivo models for 
experimentation 
34, 37, 66
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 Despite the success seen in these experiments, there is concern for use of high 
concentrations of the estrogen due to clinical results which indicated that it is 
prothrombotic 
67
. Clinical results of estrogens used to treat men with prostate cancer have 
shown increased risk of thromboembolism. This is especially dangerous for individuals 
with limited mobility because clots can form and more easily block circulation in lower 
extremities. If used in high doses or administered systemically, 17β-estradiol could cause 
this side effect, which could be especially deleterious
68,34
.  There is also some concern 
due to possible carcinogenicity associated with high concentrations 
67, 69
. More minor side 
effects have also been reported and could be problematic for population of SCI patients 
which is largely male
70
. For this reason, there have been experiments performed to test 
the efficacy of the estrogen when used in physiological low doses, which have resulted in 
limited side effects in clinical studies 
34, 41
. These studies have seen success in animal 
models with SCI, but further studies are warranted in an effort to increase local drug 
concentration while restricting systemic availability to limit potential side effects of the 
treatment. 
2.4. Nanotechnology for Drug Delivery 
Nanoparticles are nanoscale spheres capable of carrying drug loaded into the bulk 
or loaded onto the surface. Nanoparticles can be polymeric, metallic, or ceramic but are 
most commonly polymeric in the case of sustained release drug delivery by a 
biodegradable particle. PLGA is a common polymer that degrades by hydrolysis in the 
body. This degradation, in tandem with its biocompatibility, has made it a popular 
polymer for controlled release of drugs. Research on controlled drug delivery has 
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experienced profound expansion since the first controlled release study done by Dr. 
Folkman at Harvard in 1964 
71
. Research in the area of controlled release has advanced 
from patches to microparticles and now it merges with the field of nanotechnology to 
attempt to revolutionize medicine once more 
72
. The ability to control the release of 
incorporated drugs is appealing for many pharmaceutical applications because high doses 
can lead to side effects. These high doses are no longer necessary because of modern 
innovations in sustained release of drugs. Intravenous administration of such degradable 
particles is beginning to see application, but local administration is more fitting with the 
current technological abilities of these particles for controlled release of therapeutic 
drugs. 
There are many diseases which have drastic potential to see improved outcomes 
with the application of nano-sized drug delivery devices as a treatment modality. 
Sustained drug release is very useful in drug delivery, but often there is a need for 
localization of the particles when the location of the diseased site is unknown or 
inaccessible.  Targeting these particles to this site has the potential to effectively treat 
many diseases including cancer. A brief look into the pathology of cancer can illustrate 
the utility of nanoscale drug delivery not only to cancer patients, but to a wide variety of 
disease states which see some similar physiological pathologies. 
Current cancer chemotherapy agents have been shown to be cytotoxic and have 
many side effects in vivo. These side effects include some more familiar symptoms like 
hair loss, nausea, as well as more hazardous pathologies such as neutropenia and kidney 
failure 
22
. This inherent cytotoxicity limits the doses of these therapeutic drugs that can be 
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administered to patients. This systemic cytotoxicity is caused by the drug acting on all 
cells in the body, not just the on cancer cells. Even if new chemotherapy agents could be 
identified, there are still the overarching issues of systemic toxicity, high doses, and drug 
resistance that can build up over time. Thus, if a carrier could be designed that would 
deliver the drug only to the cancer site it would severely limit the action of the cytotoxic 
drug on healthy tissue and restrict its action to the cancer cells. This directed delivery is 
often called ‘targeting’ and may provide effective solutions for the major hurdles in 
oncology. Overcoming these barriers is the chief goal of oncologic nanomedicine. The 
ability to design these targeted nanocarriers is a distinct advantage of nanotechnology 
which allows consistent low drug doses to be delivered to the targeted site.  
 Many the physiological conditions present in cancer which make it a good 
candidate for drug delivery are also present in many diseases. The immediate response to 
a diseased state is for the immune system to attack it. The immune system response 
beyond the first line of defense in the local tissue macrophages is the delivery of other 
lymphocytes via the blood stream. Inflammation and swelling present in many disease 
states cause higher levels of local blood flow and a leaky vasculature to accommodate the 
increased response to the disease. This allows the for passive targeting and active 
targeting which can lead to accumulation of the therapeutic at the diseased site. Specific 
biomarkers are also present in many disease states and can be used to actively target the 
drug delivery system to the necessary location. However, an analysis should be 
performed to determine whether a local or systemic administration will result in better 
treatment efficacy. 
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2.4.2 Nanoscale Delivery Vehicles 
2.4.2.1. Nanoparticles 
Nanoparticles are nanoscale spheres capable of carrying drug loaded into the bulk 
or loaded onto the surface. Nanoparticles can be polymeric, metallic, or ceramic but are 
most commonly polymeric in the case of controlled release drug delivery by a 
biodegradable particle. Metallic particles have been studied for their unique properties as 
well.  
 
Figure 6: A simple diagram illustrating a common method of protein 
immobilization on a nanoparticles surface is shown on the left. A 
chloromethyl reactive group is attached to the surface of the nanoparticle 
and this group reacts with amine groups on the surface of the protein 
resulting in conjugating. 
73
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Gold nanoparticles are the earliest nanoparticles, and have been studied for a variety of 
applications. Iron oxide nanoparticles are of interest because they can act as magnetic 
resonance imaging (MRI) contrast agents and, as we will mention later, have gained 
much attention in the area of hyperthermic cancer treatment. 
 
Figure 7: An image of a nanoparticle taken with a transmission electron 
microscope (TEM) 
74
. 
2.4.1.2. Liposomes 
Nanoparticles constructed from lipids that form bilayer micelles are called 
liposomes and have a unique set of properties that makes them ideal for certain delivery 
applications. Liposomes are made up of lipids which have a structure that mimics the cell 
membrane, but lack the numerous embedded proteins present in cell membranes. The 
properties of the liposomes depend on their lipid composition. Liposomes can be 
unilamellar (single membrane layer) or multilamellar (multiple membrane layers), but the 
latter are rarely employed for biomedical applications. Liposomes were first proposed as 
drug delivery devices in 1974 by Gregoriadis et al. 
75
, and have since gone through many 
22 
 
changes to bring liposome technology where it is today. All liposomes contain 
cholesterol which provides fluidity to the membrane just as it does in the cell membrane. 
As new breakthroughs have shown how these carriers can be effective, it became 
necessary to add other components to liposomes to increase their ability to reach the 
therapeutic site. Amphiphilic molecules with polyethylene glycol 
4
 chains on the end 
were used to limit opsonization in the body and increase circulation half-life. There has 
also been attachment of certain targeting moieties 
76
 to liposomes to facilitate 
incorporation into malignant cells at the therapeutic site. 
Site specific delivery and controlled release are the main two goals for 
nanoparticles and liposomes as nanotherapeutics. Figure 3 illustrates the evolution 
 
Figure 8: The evolution of liposome as drug carriers is illustrated here in an 
image by Torchilin. Image A on the left shows the original liposomal carrier 
with two different drug types able to be loaded into the liposome. 
of liposomes as drug carriers.  (a) Represents a hydrophilic drug loaded into the interior 
of the liposome in a water soluble phase and (b) represents a lipophilic drug loaded into 
the hydrophobic liposomal wall. Later, as pictured in B, antibodies were attached to 
liposomes as targeting moieties by direct attachment (c) or using small linker molecules 
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(d). C represents the polyethylene glycol spacers developed for increased circulation time 
due to opsonization resistance (opsonin molecule (f) is repelled by PEG spacers). D 
shows the combination of previous advances with (g) being an antibody directly attached 
to the surface or the more effective design (h) with the antibody attached to the distal end 
of the PEG spacer. The most advanced liposome pictured in E illustrates the complex 
capabilities of modern liposomes with the  combination of a PEG spacer (I), a distally 
modified spacer with a targeting moiety (j), a molecule involved in biorecognition for 
diagnostic purposes. Other possibilities include cationic lipids (l) for DNA (m) 
complexation, incorporation of stimuli-sensitive lipids (n), stimuli sensitive spacers (o), 
attachment of cell penetrating moieties (p), involvement of viral components (q), loading 
of magnetic nanoparticles (r) for imaging, and colloidal gold or silver nanoparticles (s) 
for electron microscopy.
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2.4.2. Effects of Size 
The size of these nanoparticles is of the utmost importance. Particles under 1 
micron are necessary to increase the surface contact to the external system which allows 
increased loading in the case of surface attachment 
77
. It is also imperative to have 
nanoparticles that are able to travel through capillaries which are as small as several 
microns. This demand has resulted in the explosion in the field of nanotechnology. The 
biodistribution of liposomes, or where they find their final resting place in the body, is a 
factor of the size 
77
. Smaller particles are cleared from the body within minutes by the 
kidneys. Many larger particles are taken up by the reticuloendothelial System (RES) 
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which is made up of tissue macrophages such as liver macrophages, called Kupffer cells, 
and spleen macrophages.  
The ability of a delivered drug to reach a tissue is dependent on the fenestration of 
the epithelial lining of the blood vessels. There must be a high fenestration size in the 
epithelial lining to allow nanoparticles into the interstitial space 
78
. This high fenestration 
size occurs when vessels become leaky to allow more nutrients into the interstitial space 
which happens in damaged tissue, as illustrated in Figure 2. Leaky vessels are common in 
cancerous regions as well as at an inflammation site. In normal, healthy tissues, the drug 
can still reach the interstitial space and exert its pharmacological action, but only when 
the free drug is able to move across the vessel lining. This occurs much less often in 
controlled release carriers as compared to a simple injection of free drug. There are 
studies that have measured the different fenestration sizes of organs in different animals 
and there appears to be some consistency in the fenestration size of different diseased 
organs 
78, 79
. This could provide some guidelines to researchers attempting to target a 
specific organ by using nanoparticles designed with a size and targeting moiety for that 
diseased organ.  
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 Figure 9: This Figure illustrates the role that fenestrated epithelium 
(leaky vessels) play in drug delivery. Some drug is able to penetrate the 
continuous vascular endothelium, but drug in a carrier is not. This limits 
systemic exposure of tissues to the drug and isolates the drug location and 
action. This is particularly true of cancer treatment regimes which utilize 
local fenestrated epithelium as a means to increase local concentration and 
efficacy. 
77
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2.4.3. PEGylated Liposomes and Nanoparticles 
A major breakthrough in liposome and nanoparticle technology was made when 
polyethylene glycol was chemically attached to the particle surface. The human body is 
adept at removing foreign objects to prevent invasion of pathogens. When any foreign 
object enters the body, it is immediately coated by proteins (opsonized) that mark it for 
uptake by natural killer cells. This process occurs when nanoparticles or liposomes are 
introduced into circulation limiting their half-life in blood stream to several minutes. 
Thus, it becomes important for any drug carrier to be resistant to opsonization. 
Hydrophobic surfaces are more prone to protein adsorption and are therefore undesirable 
on drug carriers. This becomes a problem for particles with hydrophobic surfaces, and 
 
Figure 10: Graphical representation of a nanoparticle that has been surface 
modified with poly(ethylene glycol) (PEG). (Credit: Olga Reukova and 
Vladimir Reukov) 
27 
 
results in their rapid removal from the blood stream. Thus, the challenge to develop a 
protein-resistant coating for hydrophobic particles to prevent rapid clearance was 
presented. This call was answered by researchers Alexander Klibanov and Vladimir 
Torchilin 
4
, and several other groups simultaneously 
80, 81
, who applied a principle for 
surface coating that had been developed at Rutgers in the 1960’s 5. It was applied to 
nanoparticles a few years later by a group
82
 out of Massachusetts Institute for Technology 
(MIT) headed by Robert Langer 
83
. This technology utilizes a polyethylene glycol (PEG) 
polymer chain attached to the surface of the liposome. This PEG chain is extremely 
hydrophilic and can prevent protein adsorption. A lack of opsonization limits the immune 
systems rapid recognition and uptake of the PEGylated nanocarriers resulting in a longer 
circulation time or increased residence time in the tissue once it has vacated the 
vasculature. Otherhydrophilic spacers, such as poly (hydroxylethyl methacrylate) 
(polyHEMA) have been applied to nanoparticle systems with similar success.  
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Figure 11: Pisani et al show an ability to finely tune the size of microparticles 
constructed from PLGA-PEG polymers. The images proceed from top to bottom 
with increasing copylymer concentrations (0, 5, 10, 20, 40, 50, 60, 80, 90 and 100% 
PLGA PEG). As the copolymer concentration increases there is a more pronounced 
‘hairy’ texture to the corona of the particles. This increase is due to PEG interacting 
with the aqueous environment preferentially over the polymer core. This creates a 
solvent sphere around the particle. The images include the left column (bright field), 
the middle column (confocal microscopy), and the right column (SEM) 
84
. 
2.4.5. Methods of Nanoparticle Targeting 
2.4.4.1. Passive Targeting 
Earlier in this review, the leaky vessels present in malignant tumors and other 
damaged tissues were referenced. These leaky vessels are the result of fenestrated 
epithelium and pressure gradients between the vessels and the interstitium. This leakiness 
causes an increased flow to the cancerous site which results in an accumulation of 
nanoparticles being transported in the blood 
85
. Due to the rapid production of tissue 
vasculature at malignant sites, there is an inadequate lymphatic system presence which 
results in further accumulation due to lack of drainage. This is where PEGylated particles 
have a comparative advantage because of their extended circulation time 
85
. The outcome 
of which is a relatively high concentration of engineering particles at the cancer site 
compared to normal, healthy tissues. This effect has been aptly named the enhanced 
permeation and retention effect (EPR) by the researcher who first described it in 2001 
86
. 
Maeda also noted that there was a higher concentration of the particles in the tumor 
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tissues than the plasma. The EPR effect resulted in a very popular method of liposome 
delivery due to its convenience as well as it highly effective nature. This method of 
delivery has been called passive targeting or passive diffusion. 
There are two nanoparticle formulations approved by the United Stated Food and 
Drug Administration (FDA) that are designed to carry small molecule cancer treatments 
by passive diffusion with several more currently in clinical trials. The first nanoparticle to 
be FDA approved is called Doxil and is a liposomal formulation for the treatment of 
cancer. Doxil first received approval in 1995 for cancer treatment and received full 
approval after a several years in accelerated approval in 2003. Doxil is now approved for 
treatment of several types of cancer 
87, 88
. A discussion on Doxil and the related research 
is contained in the section on controlled release later in this review.  The second, titled 
Abraxane, is a nanoparticle built from the protein albumin and was approved in 2005 
89, 
90
. Abraxane is also discussed in more detail later is this review when discussing 
approved therapies utilizing controlled release.  
2.4.4.2. Active Targeting 
A different class of nanocarriers utilizes highly specific interactions of 
biorecognition molecules (“targeting ligands”) with specific biomarkers to achieve drug 
delivery to a tumor or other location in the body. This therapeutic methodology is 
referred to as ‘active’ targeting. This approach heavily utilizes proteins as the most 
natural targeting ligands, especially those proteins which are already involved in 
signaling and cell recognition. 
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The most common protein targeting agents used in active targeting are IgG 
antibodies immobilized on the nanoparticle surface. These immune system proteins have 
a very high specificity and can selectively and effectively localize the nanocarrier at the 
site of therapeutic need. When antibodies are immobilized on liposome surfaces for 
targeting the resulting constructs are aptly named ‘immunoliposomes’. Immunoliposomes 
91-93
 have become a very fashionable area of research over the past decade. Attempts to 
improve currently used liposomal cancer treatments have shown positive results 
94, 95
.  
While antibodies are the most common protein used for active targeting blood 
transport proteins such as transferrin and albumin, come in close behind. Transferrin, a 
protein that transports iron in the blood, is the most common non-immune targeting agent 
used in cancer treatment. Transferrin is a useful targeting moiety because it preferentially 
binds to malignant tumor cells because of increased presentation of transferrin receptors 
on the cell surface. The high specificity of transferrin and the high levels of endocytosis 
make this mechanism a popular method for targeted drug delivery. Both nanoparticles 
and liposomes have used this targeting mechanism and have shown good results. 
 Transferrin directed targeting to malignant tumors has been performed by many 
groups. Liposomal doxorubicin is again the drug of choice for many studies targeting 
malignant tumors via the transferrin endocytotic pathway. One recent study showed more 
than a five-fold increase in tumor doxorubicin concentration over the free drug and a 44% 
increase over the PEGylated liposomal doxorubicin delivery system 
96
. This study did 
show an increase in liver uptake of the transferring targeted drug, but other RES organs 
saw a decreased concentration. This study also shows a similar circulation time to the 
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untargeted drug. Another study 
97
 loaded paclitaxel inside nanoparticles and targeted 
them using transferrin on the nanoparticle surface. Mice that were treated by untargeted 
paclitaxel nanoparticles showed increasing tumor volume after ~50 days but at 80 days 
the tumor volume had decreased slightly in the targeted group.  This study showed 
increased lifetime of mice compared with controls with the only death coming after 3 
months of treatment and was seemingly unrelated to cancer. Several reviews that cover 
transferrin as a targeting agent for drug delivery are available 
97-100
. Transferrin has also 
been utilized to mediate endocytosis for nanomaterials specializing in gene delivery 
101
. 
Lactoferrin is a related enzyme in the transferrin family that was recently used as a 
targeting protein to achieve gene delivery of nanoparticles to the central nervous system 
(CNS) 
102
.Comparison of lactoferrin-based targeting to transferrin-based targeting 
showed a 5.2 times increase in CNS delivery over unmodified nanoparticles and a 2.3 
times increase over transferrin modified nanoparticles 
103
. Several quality reviews have 
been published in the area of gene delivery and can be consulted for further information 
on this elegant medicinal treatment regimen 
104-106
.  
 Actively targeted drug delivery systems such as those described here are usually 
delivered systemically, as will be discussed later in this review. The nature of targeted 
drug delivery must give a certain level of freedom to the particles so that they can 
preferentially accumulate in the tissues to which they are targeted, either actively or 
passively. Local delivery limits this freedom, although there are distinct advantages of 
local delivery which will also be discussed in the next section. 
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2.5.  Methods of Drug Delivery or Administration 
 There are two major methods of drug delivery; systemic and local delivery 
17, 107-
111
. Systemic and local delivery both have distinct advantages and disadvantages which 
are important to discuss 
10, 108
. A good understanding of the limitations and advantages of 
each delivery method will enable the researcher or clinician to make well-informed 
decisions about how to approach a particular treatment 
112-114
. The majority of the work 
published in drug delivery over the past several decades has focused on systemic drug 
delivery through intravenous administration 
13, 14, 85, 99, 99, 115, 116
. However, this does not 
necessarily an indicator that it is a model which affords better efficacy, though it may 
have garnered some favor in part because it is viewed by many as a more sophisticated 
mode of delivery. 
2.5.1.  Systemic Delivery 
Systemic delivery carries a drug which is delivered via the circulation to its target 
117
. This method of treatment carries the drug everywhere in the body and gives the 
therapeutic drug access to nearly any location so that it can play its therapeutic role. This 
method is useful for giving the drug this unrestrained access if the drug is capable of 
distinguishing its therapeutic role from other deleterious functions it can play in the body. 
However, this is rarely the case. As we have discussed previously, many 
pharmacotherapeutics cause side effects, these side effects often bring about the use of a 
controlled delivery vehicle in an attempt to diminish these effects 
118, 119
. Also, many 
drugs are only needed in one specific area of the body to perform their therapeutic 
function. For example, cancer is often restricted to a tumor, and a chemotherapeutic agent 
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need only be in high concentrations in the location of the tumor (though metastasis 
prevention through systemic delivery could be useful, but this comes at a high cost to the 
patient 
119, 120
.) Spinal cord injury is another example of a disease for which the drug is 
only needed locally. The deleterious events following spinal cord injury are mostly 
isolated to the injury site, and thus only require local treatment. 
There are many different routes of administration to deliver a drug to the entire 
system. Intravenous delivery is the most direct for most applications because systemic 
delivery is achieved by being transported through the circulatory system 
121
. However, 
this is not the only administration route and many others have been examined and show 
efficacy. Examples of other administration routes are: oral delivery 
122
,  delivery to the 
lungs and nasal cavity, often through aerosols
123-127
, buccal mucosa 
128
, topical or 
transdernal administration 
129-131
, ocular delivery 
132, 133
, as well as several others 
134, 135
. 
Some examples of systemic delivery were discussed in the previous section on active 
targeting. 
2.5.2.  Localized Delivery 
There has been a large effort made over the past three decades to develop 
effective treatments for the diseases which plague mankind. Much of this work has 
focused on drug delivery and on taking advantage of potential which this field carries 
23, 
28, 75
.  Here, we will focus on local delivery of drugs for the treatment of disease. Much of 
the work done using drug delivery vehicles for the controlled release of drugs requires 
targeted delivery, either by passive delivery or through active targeting, in order for them 
to be effective. However, as will be discussed in more detail in a later section of this 
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review, there are significant limitations to the successful treatment using a targeted 
nanoparticle. The immune system is adept at removing foreign substances, and 
nanoparticles are no exception 
85
. However, this loss of drug would be drastically reduced 
if the nanoparticle based therapy could be directly injected at the site where it performs 
its therapeutic action. This is one of several advantages to local delivery, but  these 
advantages must be weighted appropriately as local delivery is not appropriate for all 
applications. 
Local delivery, in contrast to systemic delivery, offers several other advantages 
136
. First, it prevents the large scale loss of nanoparticles in the liver and other RES 
organs, and limits the immune response to only the local tissue response 
137
. In addition, 
much lower concentrations can be used because the therapeutic will not be dispersed 
throughout the body, this results in less waste and thus a more cost efficient system, and, 
perhaps more importantly, it limits the side effects associated with high doses and drug 
accumulation in healthy tissues. Even in the most successful cases of drug delivery which 
achieve around 5% of the administered drug at the targeted site, the other 95% of the 
drug is distributed throughout the body potentially causing side effects 
113
. Local delivery 
also offers the advantage of a one-time administration of the treatment, after which 
sustained delivery extends therapeutic action. This is important not only for the comfort 
of the patient, but also eliminates the risk of patient compliance when regular dosing is 
required. In the case of local delivery, though there will be some drug which escapes, the 
majority will stay localized, especially when delivered in a controlled manner from a 
slowly degrading particle. This controlled release is shown to be more effective than 
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weekly treatments because a low consistent dose is present. Third, the drugs can be 
stabilized by the delivery system which can protect the therapeutic activity of the drugs. 
There is also the advantage of local delivery of hydrophobic drugs, which have limited 
therapeutic ability when administered as a free drug because of rapid clearance rates and 
low bioavailability. Controlled release at the site of therapeutic need allows for effective 
treatment. Fifth, controlled release of drugs over time which creates the environment for 
effective treatment of the diseased site and allows for diffusion to expose and affect all 
diseased cells.  
One major limitation to local delivery is knowledge of the exact location where 
the drug is needed and access to that location, which creates a field of interest for 
scientists working on image guided drug delivery 
138
. For example, cancer is a common 
target for nanoparticle based therapies, but cancer is hard to locate with precision and it is 
often spread over large areas and can metastasize to other tissues. This exposes one 
limitation of local delivery, as a therapeutic restricted to only one region cannot prevent 
the systemic spread of disease. Another limitation to site specific delivery is that it is 
limited to only one region, while many diseases could require the need to treat several 
regions. However, there are many diseases or injuries that would make good candidates 
for treatment by local delivery. One such disease which has been hypothesized to be 
treatable by nanoparticles through local delivery is acute spinal cord injury. Acute spinal 
cord injury occurs when the spinal cord and the surrounding tissue become mechanically 
compromised and biochemical pathways which ensue cause further degradation. This 
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injury is a good candidate for local delivery because the deleterious activity is confined to 
the region where the mechanical insult occurred. 
2.6. Technology for Controlled Release 
 Controlled release is a useful component of drug delivery devices, whether for 
local or systemic delivery. We have already discussed the advantages and disadvantages 
of systemic and local delivery including which carrier is best, and whether local or 
systemic delivery was more appropriate in a particular application. Now we will look at 
some of the available systems for controlled release with a focus on drug delivery 
systems and materials which have obtained regulatory approval. 
2.6.1 FDA Approved Nanoparticle Carriers 
 As mentioned before, there are only two nanoparticle systems which are 
approved by the FDA. The first to be approved was Doxil, a liposomal nanoparticle for 
cancer treatment first approved in 1995 
139
.  Doxil has been extensively discussed and 
reviewed elsewhere 
140-144
, so we will not go into detail here. However, there has been 
work attempting increase the efficacy of Doxil by targeting it to cancer. One of the most 
common targeting agents is the anti-HER2 antibody which targets the p-185, or HER2, 
receptor over expressed on the surface of many malignant tumor cells 
145, 146
. Park et al 
published impressive results in a study comparing passively delivered liposomal 
doxorubicin (Doxil) and HER2-targeted liposomal doxorubicin in HER2 over-expressing 
tissues 
146
. ElBayoumi and Torchilin had success in active targeting of the FDA approved 
liposomal formulation Doxil using monoclonal autoantibodies 
23
. Early studies by 
Torchilin’s group show that monoclonal autoantibody 2C5 specifically recognizes many 
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tumor tissue types but not normal, healthy tissues 
147
. The biodistribution of the targeted 
construct was followed by radiolabeling and a small increase in RES uptake was seen 
over plain Doxil with 55% of injected drug in RES organs as compared with 49% in the 
untargeted treatment. The result of the targeted treatment was a decrease in tumor size to 
25-40% of the Doxil treated group. Another study by Torchilin and Gupta showed a 
similar 2C5 targeted Doxil therapy effectively treating brain tumors in mice 
94
. They 
again showed a significant decrease in tumor to ~50% the size of the Doxil regime 24 
days after the treatment began. 
One FDA approved example of a nanotechnology based drug delivery system 
which is delivered systemically is Abraxane, an albumin based nanoparticle which is 
administered intravenously . Albumin is a serum protein that is commonly linked to small 
molecules for delivery to tumors where it preferentially accumulates, but until recently, it 
has not been used in association with nanotechnology 
148
. Novel nanoparticle constructs 
built from albumin for the delivery of paclitaxel that did not cause hypersensitivity 
reactions was designed by American Bioscience and titled Abraxane 
21
. Paclitaxel is 
encapsulated inside the albumin nanoparticle shell and delivered to the tumor site by 
passive delivery utilizing the EPR effect. Once at the tumor site, Abraxane binds to 
albumin binding proteins dubbed SPARC (Secreted protein, acidic and rich in cysteine), 
which are over expressed in certain cancers 
19
. Binding to these proteins initiates 
endocytosis and increased therapeutic efficacy over the previously used delivery via 
Cremaphor (non-aqueous polyethylated castor oil) 
20
. Delivery in the non aqueous solvent 
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is thought to have inhibited the ability of albumin to bind cell surface proteins and 
thereby prevent endocytosis and reduce the drugs impact 
149
. 
2.6.2.  Polymeric Drug Delivery Systems for Local Controlled Release 
One of the first, and likely the most successful drug delivery systems is Gliadel 
137
. This is a depot for delivery of a chemotherapeutic drug to brain cancer which is 
constructed from (poly [carboxyphenoxy-propane/sebacic acid] anhydride wafers loaded 
with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). This technology was developed 
around 1980 by Robert Langer, received FDA approval in 1996, and expanded approval 
in 2003 for local treatment of brain cancer using up to eight of the drug loaded wafers at 
the site of cancer 
150-152
. There was significant improvement in outcomes shown for those 
treated with Gliadel in several clinical trials 
153-155
. There were 59 patients available for 
long-term follow-up and 11 were alive at 59 weeks. Of these 11, 9 received the Gliadel 
wafers and two received unloaded wafers 
155
. There was an increase in survival of treated 
patients to a median of 13.8 months compared with 11.6 months in the untreated group 
155
. Despite the success shown in these studies, there is still some concern about efficacy 
156
.
157
 
Lupron Depot is a PLGA based drug delivery system which releases an analogue 
of gonadotropin-releasing hormone to stimulate hormone production by the anterior 
pituitary gland 
158
. It is used to treat a several conditions including endometriosis, 
prostate cancer, and precocious puberty 
159-161
. As can be seen from Table 2, the PLGA 
formulation is made up of microparticles for the intramuscular administration of the drug 
for controlled release over the following several months 
162, 163
. Lupron Depot originally 
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received FDA approval in 1989, after the delivered drug was approved in 1985 showing 
efficacy in treating prostate cancer 
158, 164, 165
. It was successful in treating patients by 
chemical castration instead of surgical castration and the results of the study showed that 
the chemical castration simulated the surgical castration well 
158
. It received approval 
after seeing success in other applications later 
166, 167
. 
Another PLGA based system for the controlled release of drugs through the 
polymeric implant. The delivery vehicle, called OncoGel, is constructed of a poly 
(lactide-co-glycolide) and poly (ethylene glycol) (PLGA-PEG-PLGA) tri-block 
copolymer for local administration and the controlled release of the incorporated 
paclitaxel chemotherapeutic agent 
168
. OncoGel showed a controlled release profile over 
50 days and saw less than 0.1% of the drug able to spread to other organs and blood.  
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Table 2: A list containing some of the depots for controlled release of drugs 
based on poly (lactide), poly (glycolide), and their copolymers 
169
. 
 
 
Also, animal studies showed efficacy with a dosage 10 times lower than previous studies 
without the polymeric delivery vehicle. OncoGel has not received FDA approval yet, but 
it is currently undergoing clinical trials to evaluate its ability to treat cancer in tandem 
with radiation therapy 
170, 171
. The efficacy of OncoGel clinically and future perspectives 
are well reviewed elsewhere 
172
. 
 The controlled release systems reviewed here are by no means a comprehensive 
list of the technologies which have seen success. However, it does give insight into some 
of the technologies and materials which have shown efficacy. Table 2 shows a snapshot 
of some of the successful drug delivery vehicles based on the PLGA family of polymers. 
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This illustrates the value of micro-scale particles and begs the question of whether 
nanoparticles can play a valuable therapeutic role. While the number of nanoparticles that 
have been approved is limited, increasing research in this area and a medical community 
that is growing in its knowledge, understanding, and acceptance of nanotechnology paves 
the way for effective nanomedicines to reach the marketplace.  
2.7.  Nanotechnology for the Treatment of Spinal Cord Injury 
Nanomaterials have a great potential to effectively treat spinal cord injury and 
there has been work which has seen some success, though there is still no approved 
therapy 
173
.  Several studies have been performed to evaluate the therapeutic efficacy of 
nano-materials for controlled release of different therapeutic agents in injured spinal cord 
models. Several different materials have been evaluated including silica174, PLGA175, 176, 
liposomes177, and poly(HEMA) along with other hydrogels 175, 176, 178.  
As discussed previously, there are two different delivery methodologies which are 
possibilities for nanoparticle mediated treatment; systemic and local delivery. Systemic 
delivery exposes the drug to many different tissues throughout the body and can treat 
systemic disease. Local delivery allows for sustained release of therapeutic doses of the 
transported drug at a specific injury site. This is only an effective treatment if the disease 
is confined to a certain region. However, side effects which often accompany 
pharmacotherpeutics can be limited by local delivery. There are other advantages and 
disadvantages for both depending on the specific application which have been addressed 
herein. There are certainly nanotechnology-based systems that are not mentioned which 
have been and will be evaluated in the spinal cord. Here we aim to give an overview of 
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some of the more recent work in the field, but it is not an extensive review, as there are 
other reviews on the subject 178-180. 
The treatment of central nervous system diseases, including SCI, using 
nanoparticles has been explored by several groups 
181182
. One major formulation for 
systemic delivery is poly (butyl cyanoacrylate) (PBCA) nanoparticles which have 
consistently exhibited an ability to deliver to the CNS and a capability of penetrating the 
BBB with little evidence of toxicity 
183, 184
. Several groups have shown the versatility of 
this delivery mechanism for delivery of a variety of therapeutic drugs in animal models 
185
 
186
. In vitro, protein delivery by PBCA nanoparticles 
187
 to the CNS has also been 
explored. Other nano-materials for treatment of neurodegenerative disorders are reviewed 
elsewhere 
188
. 
Local delivery can address some of the limitations of systemically delivered drug, 
if the application is appropriate. Local administration, where the drug is applied directly 
to the diseased region, is often a good alternative to systemic delivery. Biodegradable 
nanoparticles which are loaded with a therapeutic drug are used to allow for a 
controllable, region specific treatment regime. Recently, several studies using PLGA 
nanoparticles loaded with MP administered topically at the lesion site were performed
110, 
189
. Other studies have also investigated the local delivery of MP using dendrimer-based 
nanoparticles 
190
.Improvements in functional recovery and neuroprotection were 
observed in both studies. However, with questions remaining about the therapeutic 
efficacy of MP, there will be concerns about the described system. Systemically 
administered PEGylated liposomes showed an ability to cross the blood-spinal cord 
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barrier to treat the disease 177. Poly (L-Lactic acid) (PLLA) nanoparticles loaded with 
prostaglandin E1 (PGE1) were also evaluated for their ability to improve locomotor 
function in rats after induced spinal cord lesions 191. This intravenously administered 
nanoparticulate delivery system showed a significant improvement over saline control 
and a similar effect to the liposome delivered drug 191. PLGA nanoparticles have also 
been utilized to deliver therapeutic proteins to the spinal cord 192. This study showed that 
local injection of encapsulated glial cell line derived neurotrophic factor (GDNF) could 
achieve sustained release from the particle and improve neuron survival and locomotor 
function in rats 192. There are also other nanoparticles constructed from ceric oxide which 
show neuroprotection in vitro 193. These 3-5 nm particles are theorized to have anti-
oxidant activity which enables them to function as neuroprotective particles. However, 
there is some concern of toxicity for ceria nanoparticles as well as other oxide 
nanoparticles 194. 
PLGA nanoparticles have also been used in combination with hydrogels to 
facilitate controlled release of a variety of therapeutics 175, 176. Controlled release of one of 
these promising pharmacotherapeutics, anti-NogoA, offers sustained release which 
eliminates the need for an external pump or catheter, thus reducing the risk of infection 
175, 176. These studies have used nanoparticles for the controlled release of drugs in 
combination with hydrogels in an effort to maximize therapeutic efficacy 195.  They use a 
hydrogel constructed of methylcellulose and hyaluronan polymers with embedded PLGA 
nanoparticles loaded with a drug 176. This combination of PLGA particles and the 
hydrogel actually stabilized the hydrogel matrix. These composites showed no 
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deleterious effects in the two weeks following injury after insertion into the intrathecal 
space. One study utilizing this system showed a reduction in side effects typically 
associated with Fibroblast Growth Factor-2 (FGF-2), the drug delivered in the PLGA 
particles. This efficacy illustrates the potential for a combination system such as the one 
described.  
Another area of research for protection of the spinal cord after injury centers on 
carboxyfullerenes. These compounds have shown to have anti-oxidative as well as anti-
apoptotic capabilities 196, 197. This anti-apoptotic ability functions through the inhibition of 
glutamate receptor excitotoxicity. These neuroprotective abilities have drawn attention to 
the carboxyfullerenes and on their potential to treat not only spinal cord injury, but other 
neurodegenerative disorders as well 196, 198. However, despite the efficacy shown in these 
compounds, there is still much that is not known and this enigma elicits trepidation in the 
regulatory community. 
2.8.  Estrogens Encapsulated into Nanoparticles 
 There are several groups who have encapsulated estrogens into nanoparticles, 
most commonly estradiol. However, due to the fact that it is a well known drug, its 
hydrophobic nature, and that it has a reputation for side effects, it has been used primarily 
as a model drug 
69, 199-201
. Despite its use as a model drug, there has been some work 
using 17β-estradiol as a therapeutic drug delivered by nanoparticles. One such study 
examines the ability of the hormone drug to treat Alzheimer’s disease using a 
nanoparticle carrier designed to cross the blood-brain barrier 
202
. PLGA nanoparticles 
were used to encapsulate the drug and Tween-80 was used as a coating to facilitate the 
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brain delivery of the estrogenic drug. The study observed an increase in brain 
accumulation of the drug when Tween-80 was used as a coating, indicating that this 
coating increased uptake into the brain. In addition, there was a noted reduction in 
expression of amyloid beta-42, which has been implicated in the pathology of 
Alzheimer’s disease. In addition to systemic delivery, there has also been work on the 
topical application of estrogenic nanoparticles for the treatment of menopausal symptoms 
67
. These treatments have used PLGA and have showed increased uptake and a controlled 
release to limit side effects associated with the drug.  
 
2.9.  Limitations to Nanoparticle Based Targeting and Drug Delivery 
 There are several major hurdles that must be overcome for much of this 
technology to be effective and reach the market 
9
. Much of the work in nanotechnology 
has focused on systemic administration and accumulation at diseased sites, but there are 
common misconceptions in the field which can lead to an unrealistic expectation of the 
treatment efficacy of many nanoparticulate treatment modalities. Here, we will discuss 
some of these misconceptions with an eye on the future of nanotechnological 
development, which we believe has a bright future of effective treatments for a variety of 
diseases. However, we must be honest about the major barriers in the field in order to 
make meaningful steps towards future innovation. 
2.9.1. Poor Targeting 
As can be inferred from the recent work in the field of targeted drug delivery, the 
main barrier to effective treatment through systemic delivery is poor targeting. Systemic 
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administration of nanoparticulate drugs, most often through intravenous injection, has 
made great claims of success and of ther future potential of such treatments, but there 
appears to be little improvement in the efficacy of these treatment options 
31
. While 
increased circulation time and targeting moieties have improved accumulation at the 
target site, therapeutic efficacy for many applications necessitates even better targeting.  
While there is an increase in accumulation of nanoparticles in many sites as 
described by the EPR effect, it is not as large of an increase as it often appears when 
reading the literature. It has been reported that the amount of drug delivered via 
nanoparticles which actually reaches the target site is typically less than 5% 
113
. This 
indicates that 95% is elsewhere in the body. This is unchanged by targeting moieties on 
the outside of the particles. Particles in a certain narrow range (already discussed 
previously in this review) are able to avoid clearance to some degree and accumulate in 
tissues where leaky vasculature exists. Despite this increase in accumulation, which, no 
doubt, does occur, the amount of drug reaching the targeted site is far from ideal.  
Active targeting is thought by many, largely because of a body of misleading literature, to 
be a technology which can effectively corral the nanoparticles to the site where they play 
their therapeutic role. However, ‘decorated’ nanoparticles are subjected to the direction 
of the blood flow and follow the circulation in the same way as undecorated particles 
10
. 
The targeting moiety, or ligand, can only interact with its receptor if the distance between 
them is less than a half a nanometer 
113
. This distance is extremely limiting. However, 
once the particles decorated with targeting moieties reach these tissues which possess the 
receptor, the targeting agent can anchor them and even increase cellular uptake of these 
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particles, potentially increasing efficacy. An example of this, which has been referenced 
in a review on some of the limitations discussed 
10
, is shown in Figure 12. This Figure 
shows no major difference in accumulation of antibody targeted liposomes compared 
with untargeted in the tumor. There is an increased uptake of the anti-HER2 antibody  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: The percentage of the radio-labeled immunoliposomes 
accumulated in the tumor is not significantly different from liposomes which 
are not targeted with the anti-HER2 protein. However, the inset shows 
internalization of the liposomes into the cancer cells. Here, the antibody 
modification makes a large difference. Image taken from Kirpotin et al. 
111
 
 
49 
 
surface decorated liposome though, as can be seen in the inset in the Figure 
203
.  This is a 
typical response as if there is a reported increase in accumulation due to targeting it is 
typically small and not significantly different from the untargeted particle 
10
. 
A discussion of these limitations does not invalidate a discussion on advances 
which are being made, both in so-called passive targeting and in active targeting. There 
have been two FDA approved nanoparticle delivery systems (discussed earlier is this 
review). These both utilize passive delivery based on the EPR effect, but there has been 
work on increasing efficacy through active targeting. We are not attempting to discredit 
or cast doubt on either the work done in the recent past or on the potential that these 
particles have to effectively treat a variety of diseases. Many of these diseases pose 
complex pathologies which make them difficult to treat with any other therapies, and 
nanotechnology appears uniquely positioned to provide treatment. However, it is vital to 
have an understanding of the limitations present in the field so that meaningful advances 
can be made. 
One answer to the limitations seen in the ability to target drugs to the site where 
they are needed is the use of local delivery. There are several therapies have been 
approved utilizing controlled release of drugs at a specific site 
153, 155, 166, 167, 169
. If the 
injury or disease site is known and is accessible, direct administration of a drug delivery 
system that can deliver a therapeutic dose over time is beneficial, especially in contrast to 
the potential of a systemically delivered drug. There are only certain situations where 
such an application is appropriate, but if applicable, many of the limitations discussed for 
systemic delivery are not present when local delivery is achieved. 
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2.9.2. Surface Modification and Immune Response 
Another necessity for systemically delivered drugs is increased circulation time 
which is an imperative for efficient delivery. The clearance of foreign materials from 
both the circulation and the tissue is efficient and is a major barrier to effective treatment, 
especially when targeting is necessary 
9
. Questions as to protein and enzyme stability and 
efficacy in vivo once applied to a nanoparticle system also remain. Other limitations 
include the ability to add the modified PEG groups after drug formation, which is an area 
that has seen much improvement over the last few years
9
. The maintenance of attached 
targeting ligands once drugs are in the circulation is also an issue limiting the application 
of these treatment options 
9
. If the targeting ligands are lost before localization at the 
tissue then there is reduced internalization and thereby, reduced efficacy.  
Another area that limits the application these treatments from reaching the market 
is the ensuing immune response. This is related to the surface modification limitation 
because the immune response and clearance rate of the particles are directly related to 
their surface, as that is the chemistry with which the body interacts. Methods to reduce 
the immunogenicity, such as PEGylation and the use of liposomes as carriers, have made 
strides toward this goal, but it remains a significant barrier 
16
.  
2.9.3. Sterile Formulations and Manufacturing Limitations 
Another major barrier is the preparation of sterile formulations for treatment 
204
. 
Many of the sterilization methods compromise the integrity of the therapeutic or polymer 
scaffold 
205
. There are methods that can be used, such as irradiation, which remains one 
of the most popular methods of sterilization for polymeric delivery vehicles, but 
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questions remain as to the efficacy of the sterilization treatment and its potential effect on 
many proteins and polymer delivery systems 
204-206
. The ability to scale up the 
manufacture of nanoparticles for marketing once a formulation is approved is also a 
limitation 
114
.   
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CHAPTER THREE 
SIGNIFICANCE AND SPECIFIC AIMS 
3.1. Clinical Significance 
 Secondary injury plays a key role in the pathology of spinal cord injury. 
Inflammation, free radical damage, ionic imbalance, and apoptosis are all culprits in the 
etiology of secondary SCI. The damage caused by these secondary injuries begin as soon 
as the injury is sustained, but continues for an extended period of time as healing takes 
place. However, it is during the first few days following the injury when the most critical 
damage occurs. Thus, if an effective treatment option is administered early after injury 
treatment continues for one to two weeks following the injury, much of the damage could 
potentially be prevented.  
 Sadly, the current standard for treatment of SCI, methylprednisolone, is highly 
controversial and its efficacy has been questioned by many experts in the field. This 
leaves physicians with no good option for treating SCI. In answer to this need there has 
been a body of research to try and find an effective treatment option 
33, 41, 56
. One such 
treatment which has garnered attention is 17β-estradiol, an estrogen, which has been 
shown to be effective at ameliorating many of the effects of secondary SCI. This 
therapeutic effect can be attributed to the multiple therapeutic roles which the estrogen 
can assume. This estrogen is an effective anti-inflammatory agent, a potent anti-oxidant, 
and is also capable of restoring ionic homeostasis and preventing apoptosis. All of these 
effects combined have drawn attention to 17β-estradiol as a potential neuroprotective 
drug for treatment of SCI. However, there are some limitations to the use of this estrogen. 
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These include possible side effects due to the estrogenic nature of the drug, and high 
doses, which exacerbate side effects, necessitated by rapid local clearance and systemic 
biodistribution of the drug.  
 Here, we propose as a solution a biocompatible, biodegradable, PEGylated polymeric 
nanoparticle for controlled release of the drug and resistance to uptake. This nanoparticle 
will enable slow release of the drug in therapeutic levels at the site of injury. Local 
administration and the controlled release from the nanoparticle will keep the drug 
localized and prevent much of the drug clearance associated with intravenous delivery. 
The controlled release should be able to sustain a therapeutic concentration of the drug 
while limiting the dose exposed to the body in an effort to limit side effects.  
 In the long term, this work will pave the way for the development of an effective 
therapy which will prevent much of the damage caused by SCI and restore the patients to 
a high quality of life. The platform proposed here can also be applied to other 
therapeutics to be locally administered and could provide a platform for other novel 
therapies to be effectively delivered with minimal side effects and low therapeutic doses.  
 The proposed nanoparticulate estrogen delivery system may also be effective at 
treating other diseases. Estrogens are considered to be potentially influential in the 
pathological development of several major diseases. The neuroprotective role which 
estrogen plays in the treatment of SCI could be translated to treatment of Parkinson’s 
disease, Alzheimer’s disease, and multiple sclerosis should estrogen (or a lack of 
estrogen) prove to be implicated in the pathology of these diseases. For example, many 
consider estrogen to be involved in the pathogenesis of Parkinson’s disease, as there are 
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many conditions which result in a slowed estrogen production which have been 
implicated as risk factors for the disease 
11
. In short, an effective therapy to facilitate the 
controlled release of estrogens, while limiting the side effects commonly associated with 
estrogen treatment, could not only transform the currently known therapeutic realm for 
estrogens, but could expand it to treat diseases in which estrogen’s role has not yet been 
elucidated. 
  
55 
 
3.2. Specific Aims 
Specific Aim I. Development and characterization of nanoparticles for sustained 
release of 17β-Estradiol as a treatment for spinal cord injury 
Hypothesis: In this aim, we will establish an effective formula and ideal 
conditions for effective encapsulation of our estrogenic drug in nanoparticles as well as 
characterize the particles. The characterization of the particles which are designed for 
therapeutic treatment is critical. We will characterize these particles by determining 
encapsulation efficiency, particle size, and in vitro release profile. 
 We will first determine a formulation for the drug containing particles by using 
varying poly (ethylene glycol) (PEG) content to find the maximum encapsulation 
efficiency. We will then lyophilize the formed nanoparticles for long term storage. Size 
of the nanoparticles is evaluated here by both dynamic light scattering (DLS) and atomic 
force microscopy (AFM). The goal of using both methods for analysis is to ensure 
accuracy and to observe if there is any level of aggregation. Size of the nanoparticles is 
important for diffusion in the tissue, controlled release rate, and can affect the body’s 
ability to clear the particles. Degree of aggregation is also important as the particles 
should be stable individually. 
 Dosing will be evaluated based on the in vitro release rate with an eye towards 
translation of the system into in vitro and eventually in vivo studies to evaluate efficacy. 
The determination of the in vitro release rate is tricky for hydrophobic drugs such as 17β-
estradiol, so we propose the use of a protein, albumin, which is involved in the transport 
of hydrophobic small molecules in the body, to aid in drug transport. Albumin carries 
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estrogens and other steroid molecules in the body, and can function to separate the drug 
using a dialysis based delivery system described herein. This method will be evaluated 
using PLGA nanoparticles loaded with estrogen and with a liposome with incorporated 
dexamethosone. The use of two drug delivery systems as well as two drugs will illustrate 
the utility of the method. 
Specific Aim II. In vitro analysis of the estrogen loaded nanoparticles in a 
neuroblastoma cell model.  
Hypothesis: We will evaluate the neuroprotective effect of the sustained release 
estrogen in a neuroblastoma cell culture model challenged by both glutamate, an 
apoptosis inducing molecule, and hydrogen peroxide, which simulates oxidative stress. 
The newly developed nanoparticle delivery system must be evaluated for efficacy in a 
relevant cell culture model to determine its ability to treat the events following SCI. The 
cell model used here will be a neuroblastoma cell model which should respond to similar 
stimuli as native nervous system cells from the spinal column. 
This evaluation will be done by first illustrating the retained activity of estrogen 
loaded into nanoparticles by dissolving the polymer shell and delivering the once 
encapsulated estradiol alongside free estradiol to demonstrate a similar protective effect 
between the two. This, as well as an evaluation of the neuroprotective effect of the 
estrogen delivered via the nanoparticle, is demonstrated with a glutamate challenge to 
mimic glutamate excitotoxicity of the cells in the region of the injury. 
 Second, a hydrogen peroxide challenge, to mimic the oxidative stress 
following injury, will be used to evaluate the therapeutic ability of the developed 
57 
 
treatment. A dose dependent study to determine the best dose for therapeutic efficacy will 
be carried out. This study will evaluate the neuroprotective effect of the hormone when 
delivered by the nanoparticle system through controlled release. There will also be a pre-
treatment time study performed. This is necessary because of the controlled release 
component of the delivery system. Because the drug is released slowly over time, the 
maximum therapeutic effect should not be expected immediately upon administration, 
but rather should be expected after a time for release. This pre-treatment study will 
evaluate the efficacy as more time is allowed for drug release before the challenging 
agent, hydrogen peroxide again for this study, is added to simulate the oxidative stress 
after injury.  
These studies should shed some light on the dose, pre-treatment time, and 
therapeutic effect to be expected as this treatment regime is translated to an in vivo 
animal model for evaluation. However, there are some limitations to the in vitro cell 
culture model used here. The neuroblastoma model is a cancer cell model and thus does 
not exhibit the sensitivity that natural cells would show towards estrogen as well as some 
of the challenge agents. Accordingly, it is appropriate to further study these responses in 
a primary cell culture model to allow for a smooth transition into an animal model using 
appropriate, experimentally supported doses and treatment expectations.  
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Specific Aim III. In vitro evaluation of the proposed delivery vehicle using primary 
chicken dorsal root gangion neuron cell culture model.  
Hypothesis: The dorsal root ganglion neuron cell culture model is a clinically 
relevant model that should permit effective dosing to be determined. This primary cell 
line will provide a useful comparison to the neuroblastoma model utilized in prior 
experiments and should set the stage for translation into an in vivo small animal model 
for evaluation of the treatment. Here, we will perform the same dose dependence and pre-
treatment time experiments that were performed on the neuroblastoma cell model. This 
will enable a useful comparison in response and provide the researchers with valuable 
data to take the treatment to the next stage of testing. 
Hydrogen peroxide will again be used as the challenging agent and will illustrate 
the neuroprotective effect of the drug. All appropriate controls will be performed to 
establish nanoparticle efficacy. As mentioned, the overarching goal of these in vitro 
studies is the translation of the treatment which is being evaluated into an animal model 
as the next step towards providing a useful treatment for those plagued with SCI. 
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CHAPTER FOUR 
DEVELOPMENT AND CHARACTERIZATION OF NANOPARTICLES FOR 
SUSTAINED RELEASE OF 17β-ESTRADIOL AS A TREATMENT FOR SPINAL 
CORD INJURY  
4.1. Abstract 
Here, we report a both the development and characterization of a polymeric 
nanoparticle for therapeutic application to acute spinal cord injury and a technique to 
evaluate the drug release profile of hydrophobic drugs from drug delivery modalities. 
First, we show the loading potential and size of the developed PEGylated nanoparticle. 
We show that a high loading efficiency can be achieved and that the size and materials 
are appropriate for a biocompatible, controlled release system for treatment of 
traumatized spinal tissue. Second, we develop a new method for analyzing the drug 
release profile of hydrophobic drugs, and use the newly formulated particle along with 
liposomal dexamethosone to evaluate the release capability of this system. The drug 
release profile provides insight into translation of drug delivery systems into living 
models. Release profile analysis is complicated because many of the materials used to 
deliver the drugs, including most polymers, dissolve or break down using the current 
evaluation techniques. To address this issue, we use proteins as drug carriers in vitro. 
This protein mediated transport is how many hydrophobic molecules, including steroid 
hormones (estrogens, serotonin, testosterone, etc.), are transported in the body. Thus, it is 
reasonable to use these proteins in vitro to approximate the in vivo release of drugs.  
Here, we have shown that the use of a dialysis based system utilizing such a protein, the 
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ubiquitous serum protein known as albumin, as a drug carrier to aid in evaluating in vitro 
release rate.  Our results indicate that the method is capable of elucidating the release 
profile in a diverse set of drug delivery modalities. We evaluated the method using 
liposomes and PLGA nanoparticles and two model therapeutic hydrophobic drugs: 17β-
estradiol and dexamethasone. 
4.2. Introduction 
Recently, there has been a growing interest in controlled release and its 
implications for future medicine. A variety of drug release modalities have been used for 
disease treatment ranging from polymeric wafers 
153
 to polymeric nanoparticles 
82, 206
 and 
liposomes built from lipids mimicking the cell membrane 
22, 203, 207
. Nanoscale particles 
constructed from biodegradable polymers or lipids with incorporated drugs have 
increased because of their useful properties including biocompatibility, tunable 
degradation rates, varied useful morphologies, long circulation potential, and sustained, 
low dose release of therapeutic drugs 
72, 206, 208, 209
. The performance evaluation of these 
drug delivery vehicles necessitates a method of determining the in vitro release profile of 
as they elute from their carrier. Characterization of these drug delivery modalities is 
imperative for translation from the bench-top to the bedside.  
The size of nanoparticles is vital to the drug release rate as well as the ability for 
particles to be delivered to a specific site by the enhanced permeability and retention 
effect (EPR). It also affects the diffusion rate in tissues. The biodistribution of 
nanoparticles and liposomes delivered systemically by intravenous injection is a factor of 
their size 
77
. Thus, it is important for particles to have a relevant size and for it to be well 
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characterized before implementation in vivo. Evaluation of the degree of aggregation in a 
nanoparticle population is also an important characterization step. 
PLGA-PEG nanoparticles are naturally resistant to uptake in the body because of 
the hydrophilic PEG coating. This coating will limit rapid opsonization and clearance by 
preventing adsorption of proteins and molecules. Because this formulation is designed to 
be administered locally, there is likely not as much attrition in nanoparticle numbers due 
to filtration by the reticuloendotheliel system (RES) and opsonization and uptake by 
scavenger cells as there would be for intravenously administered nanoparticles. 
The FDA issued regulatory guidance to encourage experimental methods which 
reliably translate from in-vitro studies to in-vivo 
210
. They also state that ““Bioavailability 
studies where humans are used as test subjects should be minimized by implementation 
of in vivo dissolution standards that reflect in vivo drug performance.” 211 This translation 
from in-vitro to in-vivo requires an understanding of how the delivery systems will work 
in vivo, which necessitates an in vitro evaluation method which provides good in-vitro-
in-vivo correlation (IVIVC). This is a key component of drug delivery evaluation for 
safety, efficacy, and translation into clinically relevant models. 
In vitro release of hydrophilic drugs is relatively easy to perform in aqueous 
buffer. However, hydrophobic drug release is complicated by low solubility in aqueous 
solvents. Sink conditions, which dictate that the amount of solvent must be triple the 
solubility limit of the drug to perform dissolution characterization, must be met to 
appropriately evaluate the dissolution, or release, of a drug over time.  These sink 
conditions can be very difficult to meet in the case of poorly soluble drugs. This difficulty 
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has led to attempts to increase the solubility, of these drugs to make sink conditions more 
achievable. This is commonly done by adding surfactants, inorganic salts, and organic 
co-solvents (such as ethanol) to increase solubility 
211
. Surfactants are not ideal for 
controlled release modalities because many dissolve the carrier matrix resulting in 
premature release. Salts can aid in solubility, but do not provide a large improvement. 
Ethanol does not dissolve most biodegradable polymers including poly(mono-ethers), 
like PLGA, but evidence suggests that the integrity of the polymer is compromised likely 
due to large pores which appear after ethanol treatment. These strategies can affect the 
solubility of the drugs, but all have major limitations and none play an active role in the 
transport of the drug and a system (dissolution methods and their limitations have been 
thoroughly reviewed elsewhere and will thus not be discussed in detail). In addition, the 
use of additives not naturally present in the body may alter the release yielding a less 
accurate profile. 
To address the issue of in vitro evaluation of the release of many poorly soluble 
drugs, we propose the use of albumin as an active transport vehicle in a dialysis system 
for analysis of drug release profile in vitro. Albumin has been used in tandem with many 
other additives to increase solubility of some drugs 
212, 213
, but to our knowledge there has 
been no work illustrating the distinct advantage of albumin as a natural protein which can 
function both in vitro and in vivo as a drug carrier. Utilization of the proteins that are 
involved with physiological transport in vivo gives early insight in-vitro to what the 
release profile will be when translated to an animal model.  
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Albumin’s physiological function is in the transport of poorly soluble molecules 
in the circulatory system. There are many proteins whose primary function is transport, 
but albumin is the most abundant in the serum (3.4-5.4 g/dL) and can carry a diverse set 
of molecules and can cross various barriers in the body to deliver them where they are 
needed 
214
.   This protein can then be used to perform its natural function utilizing a 
dialysis membrane with a large pore size allows for the easy passage of albumin across 
the membrane while preventing drug carrier loss. This system allows for passive 
diffusion of albumin both without bound drug and albumin-drug complexes for the active 
removal of released drug from the drug carrier. There are two advantages of this in-vitro 
delivery system. First, the protein involved in transport of many poorly soluble drugs is 
 
 Figure 13: Crystal structure of bovine serum albumin protein model from 
the Protein Data Bank (PDB) database.  
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used to mimic the in vivo transport of the drugs and provide an accurate in-vitro-in-vivo 
correlation (IVIVC). Second, the increased solubility of these drugs makes the 
achievement of sink conditions manageable for many drugs. One limitation of this 
albumin dialysis system is that not all hydrophobic drugs can be actively transported by 
albumin. There are many drugs, especially steroidal drugs, for which this system will 
likely perform admirably, but there are limitations. However, hydrophobic molecules 
which play a functional physiological role, or drugs which are structurally similar, will 
likely be transported by albumin or another transport system.  
4.3  Research Methods  
4.3.1. Materials  
L-α-Phosphatidylcholine(PC) from egg yolk, Cholesterol (Chol), and 
Dexamathasone (DEX) were purchased from Sigma- Aldrich (St. Louis, MO). 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DSPE-PEG2000) (PEG-lipid) was purchased from Avanti (Alabaster, AL).Phosphate 
buffered saline (PBS) was purchased from VWR (West Chester, PA). 17β-estradiol, 
50:50 poly (lactic-co-glycolic acid) alternating co-polymer (Mw 7,000-17,000), and 
PLA-PEG (MW 5,000 PEG:5,000 PLA) block copolymer were purchased from Sigma- 
Aldrich (St. Louis, MO).Bovine serum albumin was purchased from SeraCare (Milford, 
MA ). DMSO, Chloroform, Acetone and other organic solvents were purchased from 
VWR. Antibiotics & Antimycotics (AA) were purchased from Cellgro (Manassas, VA). 
A Synergy microplate reader (Bio-Tek Instruments, Inc., Winooski, VT) was used 
for specrophotometic analysis of an MTT-based cell proliferation assay and to analyze 
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steroid concentrations.  Spectrum/Por Biotech Cellulose ester membranes with a 300,000 
kDa  (MWCO) from Spectrum laboratories Inc. (Rancho Dominguez, CA) were used for 
dialysis.  
Nanoparticles were characterized by zeta potential measurements using a 
ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY). The samples containing 
protein-nanoparticle conjugates were diluted 1:100 in de-ionized water to obtain the 
appropriate particle concentration. Data presented are the average of the measurements of 
three separately prepared samples each analyzed in 5 runs.  
The estrogen nanoparticles were characterized using an Asylum Bio-MFP3D 
atomic force microscope (Asylum Research, Santa Barbara, CA). AFM experiments were 
conducted in tapping mode in ambient conditions using Olympus AC160TS cantilevers 
backside-coated with aluminum with a spring constant of ~40 N/m. 
For AFM sample preparation, a mica substrate surface was washed in reagent-
grade acetone and then thoroughly rinsed with de-ionized water. The top layer of mica 
was then removed by adhering tape to the surface and quickly removing it, thus revealing 
a new layer of atomically flat mica for imaging. A 10-20 µL drop of the nanoparticle 
suspension was placed on the substrate surface, incubated for 6 min, and dried under 
airflow. 
4.3.2  Formulation development and loading efficiency  
4.3.2.1. PLGA nanoparticle recipe formulation study  
Before the drug loaded nanoparticle could be characterized and tested in disease 
models, the exact nanoparticle formulation had to be elucidated. The drug loading 
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efficiency was of paramount importance since this strongly dictates the cost efficiency of 
producing such a therapeutic. In order to determine the most efficient formulation for 
loading, two different polymer recipes were tested. First, 12.5 mg of Poly(D,L-lactide-co-
glycolide) (Mw 7,000-17,000) was mixed with 5 mg PEG-PLA (poly [ethylene glycol] – 
poly [lactic acid]) copolymer (Mw 5,000 PEG:5,000 PLA) in acetone. This formation is 
designated by its PEG content of 25% by weight. A second formulation with 10% PEG 
was also tested. This formulation used 20 mg of PLGA mixed with 5 mg PEG-PLA 
copolymer. Both formulations began with 2 mg 17β-estradiol as the starting weight. The 
10% PEG formulation was determined to have a better loading yield and was used in all 
ensuing work done on this project.  
4.3.2.2. Synthesis of PLGA nanoparticles  
PLGA nanoparticles were chosen to deliver the drug in this study because they 
have a proven track record of safety in humans 
82, 206
.  Nanoparticles will be constructed 
using the nanoprecipitation method as previously described 
215, 216
. Briefly, 50:50 PLGA 
was mixed with PEG-PLA copolymer, and an estrogen in 10:2.5:1 (wt.) ratio, as decided 
in the formulation study. This was dissolved in acetone to obtain a 5 mg/mL polymer 
solution. This solution will be added drop-wise to 20 mL of de-ionized water in an 
ultrasonic water bath and sonicated for 30 minutes. The formed particles then will be 
separated by centrifugation (7500 rcf) for 2 hours, washed three times with de-ionized 
water and resuspended in PBS buffer.  
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4.3.3  In vitro drug release profile  
Typically, drug release is performed in a physiologically relevant solution, such 
as PBS. Of course, this can only be done with drugs that are soluble in aqueous solutions. 
One way to address this solubility problem is to use a solvent in which the drug is 
soluble, but does not dissolve the polymeric shell. We performed such an experiment 
using ethanol. However, when the ethanol was added to the nanoparticles, the drug was 
immediately released into the solution. However, we propose another option for in vitro 
release profiling which utilizes proteins which transport estrogen in the serum. One such 
protein is albumin. We propose to use a novel in vitro release study using dialysis with a 
3% bovine serum albumin solution to transport the released estrogen. This setup should 
yield a more reliable release rate than other methods because it mimics native 
physiological conditions. This results in an in vitro approximation of the in vivo release 
rate. 
Nanoparticles loaded with estrogen will be placed in 300 kD dialysis bags and 
will be analyzed for remaining estrogen at pre-determined time points. Estrogen release 
will be determined using full loading as 100% of the loaded dose which was determined 
in the loading yield section described later in the proposal. Amount remaining will be 
determined using DMSO to dissolve the nanoparticle shell, releasing the estrogen into 
solution. The estrogen content can then be assayed by absorbance using a 
spectrophotometer at 285 nm, the absorbance spectrum peak for estrogens. To limit the 
background the samples are purified using centrifugation at 7,500 RCF for 2 hours and 
the supernatant is discarded. We then lyophilize the samples to remove the influence of 
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dialysis volume change and to remove all water for re-suspension in organic solvent. We 
plan to determine estrogen concentration at 0 hours, 24 hours, 48 hours, 72 hours, 5 days, 
8 days and 12 days. This will illustrate the release profile of the drug from the 
nanoparticle delivery system. This data will be used to determine the appropriate dose of 
nanoparticles for the cell culture work in the following aims.  
4.3.4.  Characterization of the drug loaded nanoparticle  
4.3.4.1  Particle Size and Zeta-Potential  
Particle size and zeta-potential were determined using dynamic light scattering 
equipment (Beckman 90-Plus Particle Size Analyzer). The size data is shown as the 
particle diameter of the size population with the largest number instead of a calculated 
effective diameter which increases diameter by accounting for aggregates. 
4.3.4.2  Nanoparticle 17β-Estradiol Loading Yield  
Estrogen loading yield was determined using UV-Visible spectroscopy following 
its absorbance at 285 nm. Nanoparticles were dissolved in dimethyl sulfoxide to release 
17β-Estradiol and background absorbance of polymer and solvent were accounted for in 
all calculations.  
4.3.4.3. Atomic Force Microscopy  
Atomic force microscopy imaging was used to characterize the size and surface 
characteristics of the nanoparticles produced. We determined the level of aggregation 
using tapping mode in air. Nanoparticles were sonicated in a bath type sonicator and 
diluted for AFM analysis. Dilutions were performed before a small drop is placed on a 
mica substrate and allowed to dry before the AFM reading is taken.  
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4.3.4.4   Freeze Drying and Long Term Storage  
Lyophilization, or free drying, was performed to preserve the drug for storage and 
prevent nanoparticle degradation during storage. Lyophilization was done according to 
the following procedure. First, the sample to be freeze dried was frozen at -80°C for 2 
hours. Following freezing, the samples were put into a flask for lyophilization. Small 
holes were introduced into the vehicles carrying the samples (usually polypropylene 
centrifuge tubes) before freezing to allow a vacuum inside the vehicle. The flask with the 
samples was then attached to the freeze dryer and allowed to dry for at least 24 hours 
before removal.  
4.4. Results 
4.4.1.  Formulation Development of PEGylated PLGA Nanoparticles 
The polymeric nanoparticles, constructed from PLGA and PEG-PLA, are 
evaluated for their ability to encapsulate the drug to be loaded. The particles are separated 
from unbound drug by centrifugation. This centrifugation is repeated three times to 
ensure purification. The loading efficiency is analyzed by directly measuring the 
absorbance of the drug which was encapsulated after dissolving the polymeric shell.  
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Figure 14: Different poly(ethylene glycol) contents change the incorporation 
efficiency of 17β-estradiol into the PLGA-PEG nanoparticles.  
As can be seen from Figure 14, the highest loading efficiency obtained was over 
50%. This data is also summarized in Table 1. There was a much lower loading 
efficiency for the nanoparticles made with 25% PEG, is likely due to a decrease in the 
amount of bulk polymer which can carry the hydrophobic drug. The 2.5% PEG sample 
saw a similar loading efficiency to the 10%, but was slightly lower. The variable 
measured here for determining loading efficiency was PEG content.  
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Table 3: Formulation development for 17β-Estradiol nanoparticles coated 
with PEG. Two different formulations were chosen to test for loading 
efficiency. Loading efficiency is shown as a percent of original drug dose with 
standard error.  
Formulation Loading Efficiency 
Final Estradiol 
Concentration 
(mg/mL) 
PGA/PLA /PEG 
Concentration 
(mg/mL) 
2.5% PEG 46.2% +/- 5.9% 0.924 
11.875/ 12.5 / 
0.625 
10% PEG 52.4% +/- 4.1% 1.050  10 / 12.5 / 2.5 
25% PEG 25.9% +/- 2.4% 0.518  6.25 / 12.5 / 6.25 
 
4.4.2.  Size Analysis of the Nanoparticles 
The size of the developed particles is also important. Here, we show by DLS our 
particles are approximately 50 nm and are generally monodisperse, or have a relatively 
narrow distribution around the reported diameter (Figure 16). We also report the 
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Figure 15: A bar graph representation of the relative number of 
nanoparticles in different sizes. The majority of the particles are centered 
around 50 nm, but there are some larger particles which are likely 
aggregations of smaller particles. 
zeta-potential to be highly negative which indicates stability of the particles and that there 
will not be substantial aggregation. As can be seen in the DLS data shown in Figure 16, 
the instrument does record particles with a larger size, but this is likely due to a small 
degree of aggregation, which is lower here than in many nanoparticle formulations  
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Figure 16: Atomic force microscopy image of the PLGA-PEG nanoparticles 
loaded with estradiol. The bright white color indicates the highest points on 
the image. 
likely because of the PEG coating. The theory that larger particles are likely aggregates is 
supported by our atomic force microscopy images of the particles. This image again 
indicates that the particles do, in fact, have a small size distribution (Figure 18), but there 
are some aggregates that can be seen in the larger scan. The size of approximately 60 nm 
is also confirmed in Figure18. The small point on the top left of each nanoparticle is 
likely due to a defect on the AFM tip which left the artifact seen in the image. 
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Figure 17: The height (or diameter) of the nanoparticles can be discerned 
from the AFM image. As can be seen at the top of the image, the size of the 
nanoparticles is approximately 60 nm, with some small variation. The lighter 
gray spots which are slightly larger than 5 nm are likely either locations 
where previously attached nanoparticles were dislodged and left a residue, or 
small areas of PEG-PLA on the charged mica substrate. 
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Figure 18: A larger scan of the nanoparticles. The majority of the particles 
are of a narrow size range. There are a few larger particles that appear to be 
aggregations of a few particles. 
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Table 4: 17β-Estradiol nanoparticle and unloaded nanoparticle diameters 
and zeta-potentials with error measurements from a particle size analyzer. 
Particle size is given by the largest population of nanoparticles produced 
with standard error. There is some variability, but this is not a major 
concern. The strongly negative zeta potential measurements signal that the 
particles are stable. 
Nanoparticle Type 
Nanoparticle 
Diameter* 
(nm) 
Polydispersity 
Zeta-Potential 
(mV) 
Estrogen 
Nanoparticles 
50 +/- 1.4 ~0.194 -58.2 +/-  3.0 
Control 
Nanoparticles 
50 +/- 0.9 ~0.080 -80.3 +/- 11.4 
*Major population of nanoparticles 
 
4.4.3.  Release Profile Determination 
We first analyzed the release of dexamethasone from PEGylated liposomes. 
Liposomes are a popular drug delivery method because of their long circulation time and 
resistance to body defense systems. DEX was released slowly from the carrier as can be 
seen in Figure 19.  The drug is slowly released over the first five days before a plateau is  
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observed. There is some variability seen in the release profile, but it is apparent from the 
profile that the drug undergoes a controlled release for the first several days. 
 Next, the method is shown capable of the elucidation of the in vitro release 
profile in a polymeric nanoparticle system loaded with a different hydrophobic drug  
(Figure 20). Here, we show that 17β-estradiol can also be transported by the protein. 
 
Figure 19: Dexamethasone release from a PEGylated liposome using our in vitro 
release profile which utilized albumin to transport the hydrophobic drug across a 
semi-permeable dialysis membrane.  
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Figure 20 shows a quick release over the first two days of the majority of the loaded drug. 
This rapid release shows the ability for the rapid transport of the drug using this method.  
We also performed the described dialysis based in vitro release determination method 
without BSA to show that the albumin itself is playing an active role in transporting the 
hydrophobic drugs across the semi-permeable membrane. Our results 
 
Figure 20: The model drug, 17β-estradiol, loaded into polymeric nanoparticle 
constructed from 50:50 PLGA  is released quickly from the particles as they 
degrade by hydrolysis. Estrogen release in the presence of albumin (Black 
squares) is much higher than the release with only buffer (Red diamonds). 
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indicate that there is almost no lost drug from the dialysis membrane, indicating that there 
must be an active transport system to carry the drug across the membrane.  
4.5. Discussion 
The lack of a good treatment for secondary events following spinal cord injury 
necessitates the development of an effective treatment. The development of a particle 
with high loading efficiency is vital to the future approval of the treatment for SCI. The 
polymeric nanoparticles form when the dissolved polymer and drug solution is added 
dropwise into an aqueous solution in which the polymer and drug are not soluble. An 
input of energy from sonication allows the nanoparticles to form instead of larger 
aggregations of polymer. In forming, the relatively hydrophobic polymer, PLGA in this 
case, will form the core of the particle and encapsulate the hydrophobic drug, and the 
PEG-PLA molecules will created a ‘solvent sphere’ of PEG on the outside of these 
particles. The solvent sphere is formed because water molecules interact preferentially 
with the hydrophobic PEG polymer. This hydrophilic layer around the particle diminishes 
the thermodynamic propensity for proteins and molecules in the body to attach to the 
particle and facilitate clearance. This PEG coating is anchored to the particle by the PLA 
groups which have a preference for the PLGA core because of their common 
hydrophobicity. The PEG plays the role of a surfactant in this case which functions to 
stabilize the hydrophobic particle in aqueous suspension. Therefore, it stands to reason 
that higher PEG ratios will result in smaller particles because there is more surface that 
can be stabilized by the PLA-PEG. Thus, to determine the highest loading efficiency we 
vary the PEG content. The results, shown in Figure 14, illustrate that the 10% PEG 
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content increases the loading efficiency with the highest loading efficiency of above 50% 
for the hormone drug in the mixture. This high loading efficiency is critical in keeping 
production costs low, which is necessary for it to reach the market. There was a similar 
loading yield in both the 2.5% PEG and the 10% PEG formulations, but in our results the 
10% PEG was higher. Thus, for all future experiments the 10% PEG formulation was 
used. 
PLGA was chosen because it is an FDA approved polymer for drug delivery and 
has been shown to have relatively little toxicity. Because the highest need for treatment is 
immediately following injury and for the first few days following injury, a fast degrading 
formulation of 50:50 PLA-PGA alternating co-polymer was used. If a need for a slower 
release profile arises, this ratio can be adjusted as needed. There are no approved PLGA 
nanoparticles as of yet, and there is a concern held by some that the nanoscale size of the 
particles could be problematic.  
As indicated, the size of nanoparticles is also critical to successful application as a 
treatment for SCI. The size of 50-60 nm is consistent between both DLS and AFM 
measurements of the size. The DLS measurements show a small number of a larger size 
population. This could be larger particles in a weighted bimodal distribution, but is more 
likely aggregation. The theory that there is a small degree of aggregation is corroborated 
by the AFM data. The larger scan shows a large number of particles with a few larger 
groups which appear to be aggregates of two to three nanoparticles. It is critical that there 
are few aggregates so that the particles are capable of diffusion in the tissue, and so that a 
consistent release rate is seen. These particles should not be in the circulation in large 
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numberes, so clogging of the capillaries is not as much of an issue here as for intravenous 
delivery, but limiting aggregation to prevent blockage of the lymph nodes, circulatory 
system, or other locations is still appropriate. 
The ability of the nanoparticle carrier to diffuse in the injured spinal tissue will 
need to be determined in order to develop a treatment best suited for effective treatment 
of SCI. Because the administration is local there is a need for a small enough particle to 
allow some diffusion through the tissue to reach the entire injured region. In theory, large 
particles in the range of microns will remain largely localized and release drug which will 
be limited in its ability to diffuse in the tissue by its hydrophobicity. In addition, small 
molecules, such as estrogens, can diffuse easily and potentially enter the bloodstream. 
This is what we want to avoid in an attempt to treat only the local region and limit 
systemic side effects.  
On the other end of the scale, small nanoparticles which are less than 20 nm have 
the potential to have high levels of diffusion and even potentially re-enter the 
bloodstream, although the level to which this will occur is unknown at this stage of 
treatment development. This can also be analyzed in future work if the therapy shows 
efficacy.  
This diameter of approximately 50 nm should be in the range of appropriate size 
for local delivery and should allow for some diffusion through tissue, but the particles 
will remain largely localized and able to treat the diseased site. It should also be able to 
do all this without causing, or at the very least reducing, many of the side effects which 
are typically associated with estrogen treatment. However, as the treatment is examined 
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the nanoparticle may need to be adapted to the characteristics required by the disease. 
This includes a possible adjustment in size as well as a possible change in polymer ratio, 
or even a polymer change if it becomes necessary. 
The in vitro release profile determination is an important characterization step 
which aids in translation of the drug delivery system from in vitro testing to in vivo trials. 
Elucidation of the release profile in the case of a hydrophobic drug is difficult for drugs 
such as 17β-estradiol and dexamethosone as they are essentially insoluble in aqueous 
media. Our analysis of the release profile of these drugs from their carriers can be used to 
determine dosing over time or to tune the release profile for the specific need. This 
analysis is typically done using ethanol as a solvent for polymeric delivery, but our  
results (not shown) indicated complete loss of the incorporated drug immediately upon 
suspension in ethanol. This is likely due to the compromise of polymeric integrity which 
prematurely releases the drug. Liposomes are also compromised structurally by ethanol, 
resulting in drug loss. Thus, we propose a new method of in vitro release profile analysis.  
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Figure 21: Graphical representation of the in vitro release model utilized to 
facilitate the release of estrogens from the nanoparticle carriers. The 
estrogen (steroid chemical structure shown) is released from nanoparticles 
(orange and grey spheres with PEG spikes), and is carried across the 
membrane by albumin (BSA protein structure shown). 
This method for assaying release of hydrophobic drugs from controlled release 
modalities is tested using two drugs (17β-estradiol and dexamethasone) delivered by two 
different PEGylated nano-sized delivery modalities (PLGA nanoparticle and liposome). It 
does not require the use of harsh organic solvents and better resembles the in vivo release 
rate due to transport proteins in physiological concentrations and an aqueous 
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environment.In the body, 17β-estradiol and other steroids are carried by transport 
proteins specifically designed to carry such hydrophobic molecules. We utilized one of 
these proteins, albumin, to facilitate the transport of the drug and obtain a relevant in 
vitro release profile. The actual degradation rate of the carriers should not be majorly 
affected by the presence of protein. This method of release profile determination is 
potentially more accurate at predicting the in vivo release profile because the transport 
mechanisms are consistent. Our release profile showed a bolus release over the first few 
days and then a slower release in the days following initial burst (Figure 20). A bolus 
release just after administration could be advantageous to avert the initial damage which 
can be catastrophic in the first few days following the injury. A lower release rate for the 
days following should still play a therapeutic role, and, depending on the therapeutic 
need, the lower concentrations are desirable in an effort to maximize the recovery with 
limited side effects 
We also performed the in vitro release determination method without BSA to 
prove that the albumin itself is playing an active role in transporting the hydrophobic 
drugs across the semi-permeable membrane. Our results indicate that there is little drug 
lost from the particles without albumin present. This indicates that there must be 
mechanism for transport facilitated by albumin to carry the drug across the membrane. 
The release rate of the drug from the carriers should not be significantly altered by the 
presence of BSA, so the drug is likely on the surface of the particles, or is precipitating in 
the membrane compartment, thus preventing any useful release profile measurement. 
Either phenomenon is not useful for in vitro evaluation because the limitation is not the 
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drug release from the carrier, but rather the solubility of the drug in the surrounding 
media. This solubility will be much higher in the body, when albumin and other transport 
proteins are there to carry the drug.  
The release of the drug over time illustrates the utility of this method over the 
traditional method which, if it works at all, is not nearly as physiologically relevant. The 
versatility of this method is also illustrated here by evaluating the release in another 
model with a different drug. This ability of the albumin to carry a variety of different 
hydrophobic drugs shows that this method can function for many different drugs. The 
limitation here is that only molecules with naturally occurring transport systems can be 
used. There are some molecules that could potentially be used because of their structural 
similarity to the natural molecule. The versatility is also evident in the ability of the 
method to reveal the release profile in a different drug delivery system other than the two 
examined here (liposomes and PLGA nanoparticles). If the release profile is slower, the 
method should still be able to reveal the profile, but this shows that if the release profile 
is extended or rapid the method exhibits utility.  
As stated, serum albumin has various physiological roles including the 
transportation of hydrophobic molecules such as fatty acids, some vitamins, and bilirubin. 
Albumin is being examined here for its ability to transport hydrophobic therapeutic drugs 
and gives insight into the release rate of these drugs using an in vitro model, but there are 
other proteins and other drugs to which this model may apply. Changes in temperature 
can also affect the release rate of drugs from their carriers. As albumin is naturally stable 
at physiological temperature and its melting temperature is measured at around 65°C, it 
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should be able to be used at higher temperatures for accelerated release studies. This is 
particularly useful for many drug release systems which release drugs over months or 
years. This makes the translational in vitro analysis requested by the FDA much more 
manageable.  
Knowledge of the release profile early in the development process is useful to 
researchers to adjust the release rate or dosing before translation into animal models. The 
high cost of pre-clinical and clinical trials makes a reliable, physiologically relevant 
release determination method an important asset to researchers in formulation 
development for drug release systems for therapeutic application. This inexpensive, 
physiologically relevant model for drug release uses a protein for drug transport just as 
the drug would be transported in vivo, thus better mimicking the release dynamics. The 
method described here is a much improved, reliable and useful method which should 
translate well into animal models due to similar dynamics. 
4.6. Conclusions 
We were able to successful incorporate 17β-estradiol into PEGylated PLGA 
nanoparticles with a high efficiency. We analyzed the effect of PEG content on the 
loading effiency and settled on a formulation using 10% PEG. The size of the 
nanoparticles was also appropriate for initial studies into the efficacy of the proposed 
treatment, and there was relatively little aggregation of the particles 
Evaluation of the release profile is also an important step in the characterization 
and analysis for in vivo efficacy. However, lack of solubility of hydrophobic drugs 
prevents the accurate measure of the release profile in a physiologically relevant system. 
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Thus, we have described a method to address this issue by using albumin, a transport 
protein, to facilitate the transport of hydrophobic drugs across a semi-permeable 
membrane. This system is useful not only because of the physiologically relevant protein 
concentration and aqueous environment, but is also able to accurately measure the release 
of drug even in the case of rapid drug release. It could also likely be applied as a model 
for evaluated accelerated release with increased temperature so the release doesn’t have 
to be performed in real time. We have shown this novel system is a useful tool in 
determining the release rate of two model hydrophobic drugs for a diverse set of drug 
carriers modeled here by PLGA nanoparticles and liposomes. 
  
88 
 
 
CHAPTER FIVE 
IN VITRO ANALYSIS OF THE ESTROGEN LOADED NANOPARTICLES IN A 
NEUROBLASTOMA CELL MODEL 
5.1.  Abstract 
 Spinal cord injury is a disease which can severely limit mobility and quality of 
life. Currently, there is no good treatment for individuals with acute spinal cord injury as 
the only treatment is highly controversial due to questions of efficacy. In the absence of a 
good treatment option, 17β-esteradiol has garnered attention for its relevant therapeutic 
abilities. However, the application of this estrogen is limited due to concerns of systemic 
side effects. In answer to these concerns, we propose the incorporation of the hormone 
drug into surface modified nanoparticles. These polymeric nanoparticles, which avoid 
uptake in the body, will allow for a sustained release of therapeutic levels of drug over 
time. This will limit the ability of the drug to reach distant tissues and cause deleterious 
side effects as well as well as endow an extended therapeutic effect. The in vitro 
evaluation of this system is performed here in a neuroblastoma cell model. We evaluate 
this system for efficacy and show its efficacy in protecting the cells exposed to multiple 
SCI-like events including glutamate excitotoxicity and oxidative stress. 
 
5.2.  Introduction 
Spinal cord injury is a debilitating condition which renders many with limited 
mobility. There are about 12,000 new cases of spinal cord injury each year with 265,000 
cases estimated in 2010 
32
. These injuries occur when a mechanical trauma to the spinal 
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column causes a disruption of the structural integrity of the spinal cord and the 
extracellular matrix is damaged as well as cell death. The injury stemming from the 
mechanical force is referred to as primary injury. However, the damage continues to 
progress for several days to weeks after the primary injury 
43
. This damage is caused by 
biochemical cascades which are initiated when damage is caused to the spinal cord. 
These biochemical events leading the more extensive damage are called secondary events 
or secondary injury.  
 The effects of secondary injury include immediate effects from inflammation 
which is partially characterized by the influx of microglia (macrophages of the central 
nervous system) and neutrophils to up clean the site 
38
. These cells release reactive 
oxygen species (ROS) which are also released due to ischemia/reperfusion injury which 
is also characteristic of SCI 
39
. These ROS cause local oxidative damage to the tissue 
39
. 
The compromise in the integrity of the blood brain barrier when an injury is sustained 
causes an influx of glutamate into the spinal cord tissue 
40
 
41
. Glutamate is maintained in 
the spinal cord, but in a lower concentration than in the rest of the body and the loss of a 
barrier causes dangerously high levels of glutamate which lead to glutamate 
excitotoxicity, triggering apoptosis 
42
.  
 The current treatment for acute SCI is methylprednisolone, which many doctors 
consider to lack sufficient therapeutic efficacy to be used for SCI patients 
41
 
46,50-52
 
1, 49
. 
This has led to research into other potential treatment options. One such option which has 
garnered some attention is 17β-estradiol. This hormone has been shown to be involved in 
several protective mechanisms which are relevant in SCI 
37
. This estrogen is an anti-
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inflammatory agent, an anti-oxidant, and an anti-apoptotic drug. Its anti-inflammatory 
abilities come from its inhibition of microglial activation 
65
. It is an antioxidant, just as 
many other steroids are antioxidants, although the exact mechanism is unknown 
64
. 
Finally, it blocks glutamate receptors and prevents the downstream apoptosis triggered by 
glutamate excitotoxicity 
40, 41
. However, despite the positive therapeutic ability that this 
hormone has shown, there is significant concern over potential side effects, especially if 
delivered systemically in high doses 
6834
. The primary side effect of concern is related to 
the cardiovascular system , because estrogens can be prothrombogenic which is 
especially problematic in a patient population with limited mobility often in the lower 
limbs which are already prone to thrombosis 
67
. There is also concern that high dose 
estrogens can be carcinogenic 
69
. There also more minor side effects which remain a 
concern including gender related effects 
70
. Because of these effects there has been 
investigation into the therapeutic effect of low dose estrogen. These experiments have 
seen therapeutic efficacy even in low doses 
34, 41
. However, rapid clearance of the 
hormone limits efficacy of free drug administered in low doses. 
 Nanotechnology offers a unique solution to the problem of systemic toxicity and 
high doses. Nanoparticles can be used to carry the drug and slowly release it in 
therapeutic levels at the site of injury 
72
. The larger size of the nanoparticles will prevent 
the hormone drug from escaping the local injury in high quantities, potentially leading to 
deleterious side effects. The sustained low levels of drug will constantly perform their 
protective role to prevent further damage, but also will limit even the local adverse 
effects. If administered without a carrier, the drug would be given in high doses because 
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it is cleared so quickly that therapeutic efficacy dictates high doses or regular 
administration, which can lower patient compliance. However, this is not necessary with 
nanoparticle drug delivery.  
 Here, we propose the use of a PEGylated PLGA nanoparticle for the 
encapsulation and sustained release of 17β-estradiol after local administration at the site 
of spinal cord injury. PLGA is a FDA approved polymer which has been used extensively 
as a drug delivery vehicle. This surface modification will allow for an extended lifetime 
without clearance from the body, which will enable the controlled release and sustained 
therapeutic levels of drug to the injured region.  
5.3.  Research Methods  
5.3.1. Materials  
17β-estradiol, 50:50 poly (lactic-co-glycolic acid) alternating co-polymer (Mw 
7,000-17,000), and PLA-PEG (MW 5,000 PEG:5,000 PLA) block copolymer were 
purchased from Sigma- Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) was 
purchased from VWR (West Chester, PA). Bovine serum albumin was purchased from 
SeraCare (Milford, MA ). DMSO, Chloroform, Acetone and other organic solvents were 
purchased from VWR. Antibiotics & Antimycotics (AA) were purchased from Cellgro 
(Manassas, VA). 
A Synergy microplate reader (Bio-Tek Instruments, Inc., Winooski, VT) was used for 
specrophotometic analysis of an MTT-based cell proliferation assay and to analyze 
steroid concentrations.  Spectrum/Por Biotech Cellulose ester membranes with a 300,000 
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kDa  (MWCO) from Spectrum laboratories Inc. (Rancho Dominguez, CA) were used for 
dialysis.  
Nanoparticles were characterized by zeta potential measurements using a 
ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY). The samples containing 
protein-nanoparticle conjugates were diluted 1:100 in de-ionized water to obtain the 
appropriate particle concentration. Data presented are the average of the measurements of 
three separately prepared samples each analyzed in 5 runs.  
5.3.2.  MTT Cell Proliferation Assay (Measure of cell viability)  
Viability was determined using a MTT cell proliferation assay, which measures 
the viability of cells. Briefly, (3-(4,5-Dimethylthiazol-2)-2,5-diphenyltetrazolium 
bromide (MTT) was added to the wells after incubation with a challenge agent. This 
MTT reagent was allowed to react with living cells for 4 hours to produce intracellular 
purple formazan, which is insoluble in aqueous solutions. This crystal is dissolved, and 
the reaction stopped, by adding a detergent to kill cells and solubilize the formazan. 
Formazan levels were followed spectrophotometrically at 570 nm. Higher absorbance 
values indicated a higher level of viability, or more cells alive in the corresponding well. 
Background is removed from all readings before analysis was performed. Cell viability is 
calculated by:  
                       
                                    
                     
Statistical analysis of this study was performed using the student’s t-test. Error is shown 
using standard error which is calculated according to:  
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Where σ is standard deviation of the measurement and n is the number of repeats. Both 
standard deviation and standard error are reported in Table 5. 
5.3.3. Delivery of 17β-Estradiol for neuroprotection using DMSO as the vehicle  
B35 Neuroblastoma cells were cultured using DMEM with 10% fetal bovine 
serum (FBS) and 1% (50 units/mL) penicillin/streptomycin. Cell culture medium was 
changed every 48 hours and cells were passaged before confluency was reached. 
Neuroblastoma cells were seeded onto a 24 well plate and fed with 0.5 mL of media per 
well. Three wells were not seeded with cells in order to have a background reading. After 
cell seeding, the cells were incubated for 4 hours on the plate to allow for attachment, and 
then the 24 hour incubation with the drug was started. Final concentration of DMSO in 
the wells was 0.4% by volume. Both free estrogen and nanoparticle encapsulated drug 
were administered to the neuroblastoma cells. The hormone drug, freed from the 
nanoparticle, was used to verify that the preservation and encapsulation procedures did 
not cause the 17β-Estradiol to lose its therapeutic abilities. 17β-Estradiol concentration 
was in a final concentration of 37 μM in the treatment wells. Glutamate (17 mM) was 
added 24 hours after drug treatment into the appropriate wells. A positive and a negative 
control were used to illustrate the effect of the drug. The positive control contained only 
neuroblastoma cells, media, and DMSO added in 4:1 PBS:DMSO solution, no glutamate 
or drug treatment. This control showed the viability of cells without any addition, or 
100% viability. The negative control contained glutamate and DMSO as added in the 
positive control but no drug treatment. This control shows the effect of the glutamate 
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with no neuroprotectant present. DMSO delivered free drug and DMSO dissolved 
nanoparticle were prepared by dissolving the drug in DMSO and diluting the DMSO 
four-fold with PBS. This solution was then added to the wells to be treated with drug.  
5.3.4.  Delivery of 17β-Estradiol for neuroprotection using the nanoparticle construct 
as the delivery vehicle  
A similar method to that outlined for the delivery via DMSO is employed for 
nanoparticle based delivery. Positive and negative controls are both used as described 
previously, but with no DMSO. Estrogen loaded into the nanoparticle is also delivered at 
a final concentration 37 μM but delivered in PBS alone for initial experiments but other 
doses will be used in later dose dependent studies. Glutamate concentrations remain the 
same and cell viability is calculated in the same manner after the reaction with MTT 
reagent. DMSO controls were also run on the same plate to compare the effect of DMSO 
on cell viability.  
We will incubate the nanoparticle loaded with estrogen for 0 hours, 2 hours, 8 
hours and 24 hours to determine the best pre-treatment time for increased viability of the 
neuroblastoma cell line. A dose dependent response study will also be performed to 
analyze the model’s response to different concentrations of the drug when delivered by 
the nanoparticle vehicle. Several different concentrations will be used to determine the 
optimal concentrations for effective neuroprotection.  
5.4. Results 
Neuroprotective Efficacy of Estrogens Loaded into Nanoparticles 
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 17β-estradiol has been shown to have the ability to convey a neuroprotective 
effect through several protective mechanisms. Because of the hydrophobicity of the drug, 
the free estradiol is typically added via DMSO to cell culture model for evaluation of 
efficacy. The DMSO is used to dissolve the drug and deliver it to the cells. To ensure that 
the drug is still able to function in its protective role even after incorporation into 
nanoparticles, we dissolve the nanoparticle shell in DMSO and compared the protective 
ability to free estradiol also delivered via DMSO. As can be seen in Figure 6, both 
treatments are able to protect the neuroblastoma cells with P < 0.05. Threre is a small 
difference in viability that can be seen here, with a lower viability in the nanoparticle 
treatment group, but there is no significant difference between the two drug treatment 
groups. 
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Figure 22: A significant improvement can be seen in the viability of both the 
estradiol encapsulated into nanoparticles and the free estradiol. The polymer shell 
was dissolved by DMSO and both treatments were identical except for the dissolved 
polymer shell. This shows that incorporation into nanoparticles does not 
significantly diminish the therapeutic ability of the drug. 
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While performing these experiments, we noted that there appeared to be less 
viability in the cells which were treated with DMSO. When explored further, we saw 
only a small effect from DMSO alone with only a 3.5% drop in viability between positive 
controls (Table 3). However, when the cells are treated by glutamate and DMSO, there is 
a significant difference in the viability (Figure 7). When cells are treated with only 
DMSO, there is not a significant difference between the DMSO treated and those not 
exposed to DMSO (P ~ 0.1).   
Figure 23: DMSO appears to be toxic to neuroblastoma cells when in 
combination with glutamate. The effect appears to be present without 
glutamate when the positive controls with DMSO were compared (P~0.1), 
but not as significant as when glutamate and DMSO are combined (shown 
above), giving a convincing statistical significance (P<0.0005). 
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Table 5: Neuroprotection studies on estrogen loaded nanoparticles in a 
neuroblastoma cell line. The challenging agent which estrogen protects 
against is glutamate in this experiment. 
In Vitro 
Neuroblastoma 
Cell Treatment 
Average Viable Cells (%) 
Standard 
Error 
Number of 
repeats 
DMSO Delivered 
Nanoparticle 
42.25% +/- 3.16% 1.82% N = 3 
DMSO Delivered 
Free Drug 
40.07% +/- 3.49% 2.01% N = 3 
DMSO Negative 
Control 
33.85% +/- 3.51% 2.03% N = 3 
DMSO Positive 
Control* 
96.58% +/- 1.40% 0.81% N = 3 
Nanoparticle 
delivered drug 
67.41% +/- 7.49% 2.25% N = 9 
Negative Control 
(No DMSO) 
55.55% +/- 5.51% 2.25% N = 6 
Positive Control 
(No DMSO) 
100.00% +/- 2.67% 1.09% N = 6 
*DMSO Positive Control and other DMSO treatments compared to positive control (No 
DMSO). 
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However, when the cells are treated with glutamate and DMSO, the decrease in viability 
compared to the control group only treated by glutamate is significantly different (P 
<0.0005) (Figure 7). This indicates that DMSO is not the best delivery vehicle for the 
drug, even in cell culture models, but certainly not for in vivo models in future 
experiments. 
  There are several neuroprotective roles which 17β-estradiol can play following 
SCI. Figure 24 shows the ability of the estrogenic nanoparticle to significantly protect a 
neuroblastoma cell line from glutamate excitotoxicity. Estrogen was delivered in a total 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: 17β-estradiol loaded into nanoparticles is capable of significant 
protection against a glutamate challenge in a neuroblastoma model. 
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concentration of 37 μM and pre-incubated with the cells for 24 hours before glutamate 
was added. 
Dose dependence of the estradiol nanoparticles in a neuroblastoma cell model 
 As mentioned previously, the protective effect of 17β-estradiol is multifaceted. 
Here, instead of glutamate, we will test the neuroprotective ability of estrogen against 
oxidative stress. We will simulate this stress by introducing hydrogen peroxide in a 300 
µM concentration to the neuroblastoma cells.  
In an effort to determine the dosage which has the best ability to significantly 
protect nervous tissue in the spinal cord, a study evaluating the protective effect with 
varying doses was initiated. As can be seen from Figure 25, as the dose increases from 
the low dose (37 nm), to medium (0.37 µM), to the high dose (37 µM), there is an 
increased response. The lower two doses examined here are not significantly different 
from the negative control, but the highest dose does see a significant protection. The 
lowest concentration of estrogen shows a lower viability than the negative control, but 
this is within the error and there is no significant difference between the two. 
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Figure 25: Dose dependence of the treatment of neuroblastoma cells with the 
delivered estradiol on their viability after hydrogen peroxide challenge. 
Doses used are as follows: low dose (37 nm), to medium (0.37 µM), to the 
high dose (37 µM). All were pre-incubated for 24 hours. 
 
Evaluation of pre-treatment times in a neuroblastoma model before challenge by 
SCI-like event 
 Nanoparticles are used to deliver the drug to endow a controlled release of the 
drug to the injured tissue. Thus, there will be a component of time in the effective therapy 
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of SCI when this treatment regime is used. To evaluate the protective ability over time, 
the nanoparticles are administed with different amounts of time before the challenging 
agent, hydrogen peroxide to mimic oxidative stress following SCI in this case, is 
administered to the cell culture. The pre-treatment times were 0, 2, 4, 8, and 24 hours. 
 As can be seen from the data in Figure 26, there is a general increase in 
neuroprotection as more time elapses, allowing further degradation of the polymeric 
carrier and release of the drug from the particle. There is a significant protective effect in 
all treated samples, but the significance increases as the viability increases. The 8 hour 
time point does experience what appears to be an anomalous decrease in viability. 
However, there is no significant difference between the 8, 4, or 2 hour pre-treatment 
times. Thus, while at 24 hours there is certainly the highest level of protection, the data 
shown does not illustrate a difference in protection between the next three points (8,4, 
and 2 hours) though they are all significantly improved over no treatment. The level of 
significance does drop from P<0.001 for the highest three treatment times to P<0.005 for 
the lowest two points. The 2h and 8h time points do appear to be similar, but the p-values 
are different because of higher error in the 2h time point. 
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Figure 26: Neuroblastoma cells are pretreated for varying amounts of time to 
determine the neuroprotective effect at different time points. Estrogen was 
used in a total concentration of 37 µM, but the time allowed for release from 
the particles is varied. 
5.5. Discussion 
In order to show that the proposed polymeric nanoparticle delivery system is 
effective in treating secondary events, it is important to show protective efficacy in 
models simulating these secondary events. First, the nanoparticle construct shows a 
significant improvement over untreated cells when both are challenged by glutamate. It 
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should be noted that glutamate concentrations were increased in this model due to a 
limited response to normal physiological doses. This increase is likely necessary due to 
resilience inherent to the malignant cell line which would not be present in normal in 
vivo conditions. However, despite the increase in glutamate concentration, the treatment 
does show a significant protective effect. 
The effect is also seen for drug which was incorporated into nanoparticles and 
free drug both delivered via DMSO. This effect illustrates that the incorporation process, 
which includes dissolving the drug in acetone as well as sonication, does not compromise 
the drug’s therapeutic abilities. It was observed was that DMSO was not an ideal drug 
delivery vehicle as it did cause some toxicity when in combination with glutamate. Lack 
of solubility in aqueous conditions prevent delivering 17β-estradiol  in PBS or other 
aqueous buffer, so for cell culture applications, DMSO has been used in the past. Current 
estrogenic drugs are modified to increase their solubility in aqueous solutions and are 
thus not subject to delivery via DMSO or other solvent.  
The nanoparticle carrier, which shows an ability here to deliver the hydrophobic 
drug in its native state, does offer an alternative to chemical modification or delivery 
using a solvent medium. It is worth noting that the therapeutic effect of estrogens may not 
be compromised by the addition of a sulfate group (which is the most common method of 
increasing their solubility), but there may be a pathway towards approval and higher 
efficacy for unmodified estrogens as well as for other drugs which have not been used 
previously due to solubility issues. 
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Initially, the neuroprotective effect was expected to be higher than was observed 
in the lower two concentrations. Of course, the highest concentration, which was 
substantially higher than would normally occur in the body, was expected to see the most 
significant effect, unless there was a harmful effect caused by high the dose. However, 
the more physiologically relevant doses in the nanomolar range (the two lower 
concentrations) were expected to show a larger protective effect than was observed. 
Other research showed that estrogen in the nanomolar range did show a protective effect 
and if there was even 10% of the drug released in the 24 hour incubation time, the 
medium dose would have been enough to surpass the 10-100 nM doses reported to be 
neuroprotective in other studies 
40, 217
. However, it should be noted that the two 
references studies used different cell cultures models which differed in estrogen 
sensitivity by 10 fold. The cell model explored here also differs from both cell lines 
reported in these studies. 
This apparent lack of sensitivity to estrogens could be related to the cell culture 
model, but could also be related to the high glutamate concentrations which were 
required to see a response, but this is unlikely as the mode of action of estrogen functions 
by limiting the response of glutamate receptors and not a direct interaction with 
glutamate. Thus, an increase in glutamate should not necessitate an increase in estrogen 
concentration. There is expected to be a release above 10% of the loaded dose based on 
the release profile which was discussed earlier. This leads the researchers to one of two 
conclusions. Either there is not as much drug released from the particles in cell culture 
media as there was when the release profile was determined, or the neuroblastoma model 
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used here (which is a different cell line than was used in other studies) is not nearly as 
sensitive to estrogen as other cell lines. However, the DMSO delivered estrogen in the 
glutamate SCI model was also delivered in this high estrogen concentration and a similar 
effect was observed, which gives credence to the theory of insensitivity of the cell model. 
Still, in the interest of determining the best dose for translation into an animal model, 
both possibilities should be explored. 
 The pre-treatment time study shows that with more time allowed for the release of 
the drug from the degrading particle, there is an increased protection of the cells from 
oxidation and death. This trend is to be expected, but there does appear to be a protective 
effect even when there is no pre-treatment time. This implies that either a small amount 
of drug escapes immediately and plays a protective role, there is a protective role played 
as the drug releases, or the likely case in which both occur to some degree. There is a 
significant protective effect with these particles even when there is no pre-treatment time. 
This is a good sign, as the patient needing treatment for SCI often times needs to receive 
treatment as soon as possible. Current research indicates that treatment within the first 8 
hours after injury shows the most significant improvement in patient outcomes. Thus, if 
there was a long pre-treatment time necessary before any effect was seen, it could pose a 
problem for the patients and the practical efficacy of the treatment. 
The neuroblastoma cell in vitro experiments gives some useful insights into the 
efficacy of the drug delivery system. However, as mentioned, there are some weaknesses 
to this cell model. Neuroblastoma is a cancer cell line, which changes the dynamics of the 
line compared with a normal healthy line. It is a resilient cell line that appears to be less 
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sensitive than many other cell lines would be. When used in vivo, the cells would be 
much more sensitive than the neuroblastoma line has proven to be. One example of the 
reduced sensitivity is in the glutamate concentrations required for cell death to occur. The 
concentrations required were in the milli-molar range, where in vivo the concentrations 
which elucidate a deleterious effect are in the nano-molar range. There is also still some 
question as to the cell line’s sensitivity to 17β-estradiol.  Investigation into a more 
relevant primary line is appropriate. Also, the difference between the treated cells and the 
negative control are still small, and, though they are significant, a primary cell culture 
model to show the same effect with greater significance is warranted. 
5.6. Conclusion 
Overall, the treatment showed efficacy in our experiments in treating the 
secondary effects associated with spinal cord injury. We showed that the treatment 
resulted in significant improvement in cell viability both in glutamate induced toxicity 
and in oxidative stress induced cell death. There was a dose dependent effect and 
significance even with no pre-treatment time to allow for drug release from the 
nanoparticle. Just as we have shown in vitro, the controlled release should result in 
reduction to the damage caused in vivo by secondary events as well as acheive sustained 
therapeutic levels of the drug. Due to what appears to be low sensitivity in the 
neuroblastoma cell model, it is advisable to perform similar studies in a more  
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physiologically relevant cell culture model before translation into an animal model. 
Corroboration of the results here in such a model could provide the efficacy, dosing, and 
pre-treatment information necessary to make a successful translation into in vivo small 
animal studies to evaluate the efficacy of the nanoparticle estrogenic treatment.  
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CHAPTER SIX 
IN VITRO EVALUATION OF THE PROPOSED DELIVERY VEHICLE USING 
A PRIMARY DORSAL ROOT GANGLION NEURON CELL CULTURE MODEL 
6.1. Abstract 
Spinal Cord Injury (SCI) is a debilitating condition for many people, young and 
old, which causes neurological damage and can result in paralysis. Acute SCI results in 
an initial damage to the spinal cord, but secondary injury due to inflammation and 
activated biochemical pathways leading to apoptosis exacerbate the injury. There are no 
approved treatments for SCI, and the only available treatment is controversial
218
. 17β-
estradiol, an estrogen, is effective at ameliorating many of events involved in secondary 
SCI including apoptosis. However, the therapeutic effect is limited by low retention time 
of the drug at the affected location due to rapid clearance of the hormone. High doses and 
regular administration are undesirable due to side effects, problems with patient 
compliance, and a desire to limit discomfort. We propose to develop PEGylated 
nanoparticles with estrogen loaded for treatment of SCI. Our hypothesis is that the 
resistance to uptake, reduced immunogenicity, and controlled release endowed by the 
nanocarrier will enhance the efficacy of the drug when compared with the undelivered 
drug. Here we will evaluate the ability of the encapsulated estrogenic drug as a 
neuroprotective treatment in primary cells isolated from a mouse spinal cord which are 
used here to simulate spinal cord injury. 
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6.2.  Introduction 
Acute spinal cord injury is a condition which can result in significant motor 
function loss and even paralysis. There are an estimated 12,000 new cases of spinal cord 
injury each year and there were an estimated total of 265,000 people living with the 
injury in 2010 
32
. The effect of the disease on these patients is widely varied and ranges 
from almost no physical impairment to tetraplegia. 
Cost of treatment varies with the severity of the injury. The estimated lifetime 
costs for individuals of age 25 and 50 when afflicted with SCI are $1,461,255 and 
$1,031,394, respectively, for incomplete motor function loss at any level
32
. The cost of 
treatment for a 25 year old with paraplegia and tetraplegia ranges from $2,138,824 to 
$4,373,912 for individuals with injury in the C1-C4 region of the spinal cord. Those with 
tetraplegia in the lower section of the spinal cord see average lifetime costs of 
$3,195,853. The average yearly costs for treatment of a patient with incomplete motor 
function loss at any level is $321,720 for the first year and $39,077 per year after the first 
year. Needless to say, this is a high cost to those who are plagued by this disease.  
Spinal cord injury is caused by a mechanical trauma to the spinal cord resulting in 
cell death and disruption of the extracellular matrix. Common causes of this type of 
injury include vehicular accidents, falls, and sports related injuries, but are not limited to 
these only. The mechanical damage can be severe, but is not the extent of the damage. 
After the initial insult, there are biochemical events, referred to as secondary events, 
which cause further damage to the region. These events include local increases in 
neutrophils and microglia associated with inflammation 
38
, ischemia/reperfusion injury
39
, 
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glutamate excitotoxicity caused by elevated glutamate levels after disruption of the blood 
brain barrier 
40
, oxidative stress induced by several of the other mentioned events 
38
, ionic 
imbalance 
41
, and activation of apoptosis and necrosis 
42
. These events start immediately 
upon injury with the onset of inflammation and the arrival of microgia in minutes with 
apoptosis and necrosis following in the first several days and followed finally by 
revascularization and remodeling 
43
. 
The current treatment for acute spinal cord injury, methylprednisolone, is 
considered by many to be “an inappropriate standard of care” 1, 49. This serious allegation 
stems from a series of clinical trials to evaluate the drug 
46-48
 which saw no evidence of 
efficacy until a controversial post hoc analysis of the data was performed 
46,50-52
. These 
questionable therapeutic effects lead medical professionals to search for other effective 
treatment models 
41
. There have been other proposed treatments in the absence of a 
universally recognized efficacious treatment. These include but are not limited to: 
erythropoietin 
61, 62
 (which remains questionable because of a risk for thrombosis 
63
), 
minocycline (which saw some positive results 
57, 58
, but a NIH study commissioned to 
confirm the results was unable to reproduce the effect 
60
), and fullerenols (whose effect is 
positive 
54
, but it remains in question largely because of its anonymity and a certain 
degree of trepidation in the medical community towards unfamiliar and uncharacterized 
technologies). 
In the absence of a good, proven treatment model, research on the therapeutic 
effects of estrogens, specifically 17β-estradiol, began to entertain the attention of the 
medical community. Estrogens are familiar to the medical community and showed 
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several therapeutic effects which are relevant to the deleterious effects following spinal 
cord injury. These effects include an anti-oxidative action
64
, anti-inflammatory capability 
65
, and, perhaps most importantly, anti-apoptotic ability 
40, 41
. In vivo models evaluating 
the ability of the estrogens to prevent neurological damage have also demonstrated 
neuroprotection 
34, 37, 66
. However, there are concerns for side effects including 
thromboembolism 
6834
 especially in the lower limbs with an immobile patient population, 
as well as gender related problems 
70
. Studies looking into therapeutic low doses which 
limit the potential for side effects have been effective, but are limited by rapid clearance 
of the hormone from the site of injury 
34, 41
.  
In an effort to develop the most effective treatment for spinal cord injury, we 
began an investigation into estrogen loaded nanoparticles for the local administration and 
sustained release of the drug at the site of injury. Nanoparticles have been extensively 
studied for their ability to endow a controlled release profile to a drug 
72, 82, 97, 106, 206, 219
. 
Most of the nanoparticles which have been investigated for their therapeutic ability to 
date have been for systemic delivery of the drugs 
22, 30, 119, 220, 221
. However, in this case 
local drug delivery is more appropriate and will limit the side effects associated with 
systemic administration of estrogens 
168
. 
 
6.3. Research Methods 
6.3.1. Materials  
17β-estradiol, 50:50 poly (lactic-co-glycolic acid) alternating co-polymer (Mw 
7,000-17,000), and PLA-PEG (MW 5,000 PEG:5,000 PLA) block copolymer were 
113 
 
purchased from Sigma- Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) was 
purchased from VWR (West Chester, PA). Bovine serum albumin was purchased from 
SeraCare (Milford, MA ). DMSO, Chloroform, Acetone and other organic solvents were 
purchased from VWR. Antibiotics & Antimycotics (AA) were purchased from Cellgro 
(Manassas, VA). 
A Synergy microplate reader (Bio-Tek Instruments, Inc., Winooski, VT) was used 
for specrophotometic analysis of an MTT-based cell proliferation assay and to analyze 
steroid concentrations.  Spectrum/Por Biotech Cellulose ester membranes with a 300,000 
kDa  (MWCO) from Spectrum laboratories Inc. (Rancho Dominguez, CA) were used for 
dialysis.  
Nanoparticles were characterized by zeta potential measurements using a 
ZetaPlus Analyzer (Brookhaven Instruments Co, Holtsville, NY). The samples containing 
protein-nanoparticle conjugates were diluted 1:100 in de-ionized water to obtain the 
appropriate particle concentration. Data presented are the average of the measurements of 
three separately prepared samples each analyzed in 5 runs.  
6.3.2. Primary dorsal root ganglion neuron cell culture model  
Dorsal root ganglion neuron cultures were obtained from chicken embryos 
between day 8 and 10 after fertilization. The collected cells were plated on collagen-
coated 24 well plates (40,000 –50,000 cells per well), and maintained in a CO2 incubator 
in Dulbecco’s Modified Eagle’s Medium (DMEM) with L-glutamine, 4.5 g/L glucose, 50 
units/mL penicillin/streptomycin, 10% fetal bovine serum (FBS), and 25 ng/mL nerve 
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growth factor (NGF). DRG neurons are isolated by incubating the harvested culture for 4 
hours and then collecting the cells which are not attached to the dish. 
6.3.3. MTT cell proliferation assay for determination of neuroprotective efficacy in a 
primary neuron cell culture model  
The neuroprotective ability of the proposed estrogen delivery system will be 
evaluated in a similar manner to that performed on the neuroblastoma cell model. 
However, we will see a difference in the response as this is a different cell model which 
will respond differently to the challenge as well as the treatment. Hydrogen peroxide 
concentrations of 1.5 mM will be used to induce apoptosis in the cell culture model. 
When delivered by nanoparticles, we will sustain the release of a therapeutic dose over 
the first few days after injury, a time frame which has been shown to be critical. A 
positive and a negative control were used to show efficacy. The positive control 
contained only neuroblastoma cells and media, no glutamate or drug treatment. This 
control shows100% viability and is the standard by which other viabilities will be 
compared. The negative control contained hydrogen peroxide as a challenge but received 
no drug treatment. Viability will be evaluated as previously described using the MTT cell 
proliferation assay. Statistical analysis will be performed using the student’s t-test and 
presented using standard error as described above. 
6.3.4. Dosing determination in primary DRG neurons and the dependence of 
neuroprotection on dose of the proposed estrogen loaded nanoparticle 
We also determined the most effective dose for use in in vivo studies that will 
continue the evaluation of the treatment regime. The dose was determined by 
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administering hormone doses from the nano-molar range to the micro-molar range of 
concentrations. The efficacy will be determined by cell viability using the MTT cell 
proliferation assay after treatment. Low doses of estrogen have been shown to be 
effective at ameliorating many of the effects seen in SCI. We plan to use the lowest 
effective dose of the nanoparticle delivered drug. The total concentrations delivered in 
the nanoparticles we will use are as follows: High (37μM), Medium (3.7 μM), Low (0.37 
μM or 370 nM), and lowest (0.037 μM or 37 nM). However, sustained release of the 
hormone over time results in a lower available dose at any specific time than would be 
available if there was no controlled release. Thus, while the total dose is listed, only a 
fraction of this is released per day. There is likely to be some variation in drug release 
rate over time. The nanoparticle are designed such that there will be a bolus release when 
first administered. This can be advantageous because higher doses are useful for 
treatment immediately after injury, but sustained regional release at lower doses will 
continue to protect the tissue in the region during the critical window after injury 
6.3.5. Study on pre-treatment of cells with the nanoparticulate 17β-Estradiol and the 
resulting efficacy. 
The goal of the pre-treatment experiment is to limit the pre-treatment necessary 
for efficacy as much as is possible. Wells seeded with our cell culture line will be 
pretreated with the estrogenic nanoparticle to determine the best time for pre-treatment. 
The ideal scenario is to not need any pre-treatment, as the drug would be effective 
immediately upon exposure to the cells, but would also maintain therapeutic levels after 
initial administration. We will vary the pre-treatment times with the maximum time of 24 
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hours. We will look at the following pre-treatment times: 0 hours, 2 hours, 8 hours, and 
24 hours. Pre-treatment efficacy will be evaluated using the MTT cell proliferation assay 
to determine cell viability when exposed to the drug as described previously. 
6.3.5. Study of treatment efficacy using different treatment windows with primary 
cells as an in vitro model of spinal cord injury 
The goal of the treatment window study is to evaluate the neuroprotective effect 
of the estrogenic nanoparticle treatment regime after SCI like conditions are induced. 
Wells seeded with our cell culture line will be treated with the estrogenic nanoparticle to 
evaluate the treatment efficacy after challenge with hydrogen peroxide as described 
previously. We will vary the times with a maximum window at 4 hours after treatment. 
We will look at the following treatment window times after challenge: 0.25 hours, 1 hour, 
and 4 hours. Treatment efficacy will be evaluated using the MTT cell proliferation assay 
to determine cell viability when exposed to the drug as described previously. 
6.4. Results  
Dose dependence in a primary dorsal root ganglion cell model 
 In the interest of obtaining evidence to corroborate the protective effect observed 
in neuroblastoma cells, we use a primary cell culture consisting of embryonic chicken 
dorsal root ganglion cells. The dose dependence shown in Figure 27 illustrates the effect 
which the drug can have in protecting from secondary effects. In this case, oxidative 
stress is modeled by using hydrogen peroxide to induce the stress which damages the 
cells. Figure 9 shows that there is an increase in significance for the same dose when used 
to treat the primary cell model when compared to the treatment of the neuroblastoma 
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model. The significance of the neuroblastoma response (P < 0.01) was lower than that of 
the primary cells (P = 0.0001). The response in the primary cells was such that a 10 fold 
lower dose (3.7 µM) was evaluated and nearly reached significance (P = 0.053).  
 In this case, a higher dose of hydrogen peroxide was required to induce cell death.  
However, the significance of the improvement is higher than in the neuroblastoma dose 
dependence for the same treatment dose which was used in the neuroblastoma model. As 
mentioned,  in the high dose of estrogen applied to neuroblastoma cells there was a 
significant improvement , but in the primary cell line with the same dose saw an even 
higher level of significance.  The lowest two doses shown are lower than the negative 
control, just as was observed for the lowest dose in the neuroblastoma line, but again, this 
is within the error of the measurements and there is not a significant difference between 
them. While the range of doses did not change between models, the response appears to 
be more significant in the primary cell line.  
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Figure 27: Dose dependence of primary DRG neurons when treated with 
varying concentrations of our estrogen drug delivered by PLGA 
nanoparticles. 
Pre-treatment of the primary cell culture model to evaluate efficacy 
 We also performed a study of the effect of pre-treatment time on the 
neuroprotection of the treatment, just as was done with the neuroblastoma model 
previously. Here we show a trend which generally decreases with the time allowed for 
the polymeric shell to degrade. There is a very high level of protection in the 24 hour pre-
treatment. The viability is almost up to the level of the positive control, which did not see 
hydrogen peroxide as a challenging agent. The significance for this highest point (P < 
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0.0005), is lower than the P-values we saw for the neuroblastoma model and, again, the 
treatment efficacy shows a higher level of significance in the primary line than in the 
neuroblastoma line. This is good news as the primary line should be more indicative of 
the in vivo response. The other three treatment times also showed significant 
improvements over the untreated negative control as well. The 0h time point does diverge 
from the expected trend as the viability increases to a higher level than was seen the 2h 
treatment. However, there is no significant difference between the two, despite a modest 
increase in the significance of the 0h treatment over the 2h when both are compared to 
the untreated control. 
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Figure 28: Pre-treatment of primary neurons with the polymeric 
nanoparticle to protect against oxidative stress induced to simulate SCI. 
Treatment window study in a primary cell model 
A treatment window study to evaluate the efficacy of the treatment method was 
performed using hydrogen peroxide as the challenge agent. The treatment was added at 
three time points following the addition of the challenge agent which was added to 
simulate SCI injury. This study gives insight into the ability of the treatment to play a 
neuroprotective role even when used after injury, as would be the case in the clinic. The 
results (figure 12), show significant neuroprotection at 0.25 hours after the SCI 
conditions are induced, with decreasing viability in the following time points. When the 
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pre-treatment and treatment window studies are combined to give a complete picture of 
the response to treatment, a trend emerges which shows a decreasing viability with time. 
This trend is expected, and can be clearly seen in figure 13. Cell death occurs rapidly 
upon the addition of the challenging agent in the cell culture models, but the 
physiological response to spinal cord injury leading to cell death is much slower. This 
physiological response is extended to several days following the initial insult. 
 
 
Figure 29: Estrogen loaded nanoparticles in 37 µM concentration incubated 
with primary DRG neurons 0.25 h, 1h, and 4h after a 24h challenge with 
hydrogen peroxide show a neuroprotective effect only in the earliest 
treatment time. (n=3)  
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Figure 30: Combination of the treatment time data illustrates the trend of 
increasing viability with increased drug release time allowed. Drug was 
delivered in 37 µM concentration. 
6.5.  Discussion 
The observed response sheds light on the potential therapeutic effect that this 
treatment could have on a patient population without a good treatment option. The 
primary cell culture model was primarily examined for two reasons. First, we want to 
show that the treatment was effective in multiple SCI cell culture models including a 
primary cell model which would likely be more sensitive to the hormone drug. This 
123 
 
model was chosen because it will provide a more physiologically relevant model that 
should aid in the translation of the treatment from in vitro to in vivo in small animal 
studies. Second, even though significance was achieved in the neuroblastoma model, the 
model was resilient and the significance was not as high as we believed it would be in a 
more relevant model. Also, the appearance of a lack of sensitivity to low estrogen 
concentrations gave credence to a further examination of the efficacy in a more relevant 
cell culture model.  
While efforts will be made to ensure a mostly pure line of primary dorsal root 
ganglion cells, there will be a small degree of other spinal cord cells present including 
glial cells. This will only better mimic the response that should be expected in vivo 
because the in vivo environment will most certainly contain a variety of cell types 
arranged in the spinal column. 
 One of the expectations in using a primary cell model was that it would be more 
sensitive to estrogen than the neuroblastoma model appeared to be. However, the same 
high concentration of estrogen was required here to see significance. There was a higher 
level of significance, but a new intermediate concentration which is 10-fold lower than 
the high concentration narrowly missed significance. This implies that there was a higher 
level of sensitivity to estrogen in this model as a significance of P < 0.01 was seen for the 
highest concentration in the neuroblastoma model and the level of significance here for 
the same concentration was much lower at P < 0.0001. Despite the inability of the lower 
concentration to reach significance, it does appear that this model is more sensitive, as the 
level of significance of the 10 fold lower concentration approached significance (P = 
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0.053) and the significance in the neuroblastoma model was only modestly lower, but 
notably significant  (P < 0.01). Still, the model does not reach the level of sensitivity tio 
estrogen in low concentrations that was seen in other cell culture models 
40, 222
.  
 The lowest concentrations not reaching significance raises questions as to why 
this did not occur. The possibility does exist that it is related to the cell culture model, as 
it appears that the primary model is more sensitive to estrogen than the neuroblastoma 
line. In the referenced studies which saw significance in neuroprotection even at nano-
molar range doses, DMSO was used as a delivery vehicle. It could be that a decreased 
solubility of the estrogen in the cell culture medium compared with DMSO slowed the 
release from nanoparticles or otherwise limited availability of the drug. This reduction in 
available estrogen could account for a change in the response of the cell lines. If this is 
the issue, the presence of albumin along with other proteins which actively transport 
hydrophobic molecules such as estrogens in the body will increase the release rate in vivo 
and could result in a more dramatic neuroprotective effect, or an similar effect with a 
much lower dose. 
In the pre-treatment study, the fact that there is a significant protective effect even 
in the lowest example of viability is encouraging. The early treatment of spinal cord 
injury has been shown to be critical in effective treatment. So the significant 
improvement even with no incubation time shows that this treatment could immediately 
begin ameliorating the effects of secondary spinal cord injury. What is more encouraging 
is that 48 hours after administration of the drug (24 hour pre-treatment time followed by a 
125 
 
24 hour incubation with hydrogen peroxide) there is significant improvement almost to 
the level of complete viability in the pre-treatment study.  
Of course, administration of the treatment before the simulated secondary events 
begin is not a scenario that is relevant to the clinical treatment of SCI patients. However, 
it does give insight into the therapeutic ability of the treatment model. The treatment 
window study does show evidence of treatment efficacy after injury conditions are 
present. This indicates that the treatment will play a neuroprotective role even when 
administered while the secondary effects are causing further damage to the region. It is 
important to note here that while cell death occurs within the first few hours after 
secondary conditions are induced in vitro, this process is much slower in vivo, taking 
several days to cause such high level injury. We expect that the treatment will be 
effective in preventing cell death in vivo due to the larger therapeutic window in vivo. 
This indicates that our increasing therapeutic efficacy in vitro, showing the highest 
measured level of efficacy at 24 hours after treatment, should be effective in treating 
secondary injury both early as indicated in the therapeutic window study, and extending 
for at least 24 hours after administration. If this treatment system continues to show 
efficacy, future studies will allow for further evaluation in animal models with induced 
spinal cord injuries. 
The significance of the high doses is noteworthy and indicates the potent ability 
of the evaluated drug to effectively prevent some of the secondary damage after SCI. The 
outcomes here illustrate the efficacy of the system and support the further evaluation of 
the system.  Studies in animal models of spinal cord injury to continue the treatment 
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evaluation are warranted after the in vitro success demonstrated here in a primary cell 
culture model. 
6.6. Conclusion  
In summary, the nanoparticle based estrogen delivery system shows efficacy in 
the primary cell line examined here. This effect was more significant that was seen in the 
neuroblastoma model. The higher level of physiological relevance of the primary 
response gives credence to the continued evaluation of this treatment as a good option for 
treatment of acute SCI. This also implies that the treatment model should have a more 
pronounced effect in an in vivo model than would be expected from only seeing the 
neuroblastoma outcomes. While there are still questions to be answered, at this stage, 
evaluation of the proposed treatment is warranted in a small animal in vivo model. This 
will shed more light on the potential of the system to effectively treat SCI in the future. 
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 CHAPTER SEVEN 
CONCLUSIONS AND FUTURE RECOMMENDATIONS 
7.1 Conclusions 
Overall, the incorporation of estradiol into nanoparticles for the local, sustained 
delivery of the drug to prevent the secondary effects following spinal cord injury was 
successful in our in vitro experiments. Our goals were threefold in approaching the 
development of an effective treatment modality. First, we developed an effective formula 
for high encapsulation and then characterized the construct. Second, we evaluated the 
neuroprotective efficacy, dose dependence, and the effect of pre-treatment time in a 
neuroblastoma model. However, the resilience of the cell line necessitated another model. 
Thus, our final goal was to analyze the therapeutic efficacy of the developed drug 
delivery system. The combination of these three goals paves the way for translation into 
an animal model study to further evaluate the treatment. 
 The first goal leads to several conclusions. First, we achieved a high 
incorporation efficiency of the drug into the particle population. This high loading yield 
makes the proposed delivery system a feasible option for treatment. If the loading 
efficiency were low, then the cost to produce the treatment would be higher. Also, 
perhaps more importantly, there would have to be a larger dose of nanoparticle 
administered to the patient to see the same response. This would limit the successful 
application as increased doses could lead to increased inflammation due to acid 
degradation products from the biodegradable polymers. There has not been a strong 
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enough inflammatory response to limit the application of other PLGA delivery systems, 
but limiting the dose of polymer is appropriate nonetheless.  
Second, we analyzed the size by DLS and AFM and saw that the size was 
appropriate for local delivery over a several day therapeutic window following the 
primary injury. With a size of approximately 50-60 nm, they fall in a narrow window of 
size where a useful effect should be able to be achieved. Very small particles could see 
two barriers for our application in vivo which could limit their efficacy. Small particles 
are usually associated with renal clearance which would be limited because these 
particles are administered locally. Although this is not a major issue, there are other 
issues. Small particles would have a limited load which they could carry. Also, small 
particles are much more capable of diffusion within the tissue, which could allow the 
drug to spread outside of the region of interest. Larger particles can also negatively affect 
the diffusive ability of the treatment. Since the treatment is to be administered locally, 
there must be some ability of the treatment to spread through the injury to treat the entire 
region. If the particles are too large, there will be a limited ability to do this. Again, the 
typical limitation in size of particles is due to clearance, but this time on the larger scale. 
The liver clears out larger particles, but this barrier is avoided by local delivery of the 
drug. If intravenous administration was used, even if the particles small enough to avoid 
rapid complete clearance, a large fraction would still be removed before any functional 
role could be realized. 
The release profile in which we utilized albumin as a transport vehicle for the 
drug showed the desired initial bolus release with a slower release after the first two days. 
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As discussed in the literature review, the majority of the deleterious effects following 
spinal cord injury occur within the first few days. Thus, the release profile appears to be 
tuned to the needs dictated by the pathology of the disease. However, if a need surfaces 
requiring an adaptation of the profile to a slower release rate so as to provide a protective 
effect for longer after the injury, this could be easily performed. This current profile 
should be able to effectively limit the immediate negative effects following injury in the 
first few days, and limit the response in the week or two following.  
The in vitro release method also has other applications. Our results only show two 
possible drugs for which this method can be applied. However, there are a wide variety of 
drugs that are carried by albumin in the body, and if another protein is used, it opens up 
the application to encompass almost any biologically relevant hydrophobic molecule. 
This, in combination with the thermal stability of albumin and many other proteins at 
elevated temperatures, could provide a good system for measuring the release of drugs in 
an accelerated fashion by using higher temperatures. In addition to these advantages, it 
also likely provides a more accurate release profile to that which will be seen in vivo 
because the environment is similar. Many of the major components, including the 
aqueous ionic buffer, temperature, and transport proteins are present. Apparently, there 
are many other factors which affect release in vivo, but this model provides one more 
variable in common with in vivo release.  
The in vitro models are able to give further insight into the efficacy of the 
treatment. The neuroblastoma in vitro model shows that estrogen delivery by DMSO 
causes toxicity when combined with glutamate. However, estrogen delivered by 
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nanoparticles shows an ability to protect against the damage caused by glutamate 
excitotoxicity and against oxidative stress induced by hydrogen peroxide. These 
neuroprotective effects, in combination with the anti-inflammatory capabilities of 
estrogens, illustrate that this is a treatment with potential for high levels of therapeutic 
efficacy.  
The dose dependence showed that a high total dose of 17β-estradiol was required 
to see a significant protective effect. However, the amount of drug released in the 24 hour 
incubation time is likely much less than the total amount of the hormone which was 
loaded into the particles. The release study described in chapter 4 does give insight into 
the amount of drug which would likely be released, but could be more closely correlated 
to in vivo release than what would be seen in an in vitro model. Despite some questions 
which remain, the study did exhibit neuroprotective efficacy against both oxidative stress 
and glutamate excitotoxicity. 
There was a significant protection noted in all time points of the pre-treatment 
time study. The level of protection did increase as more time was allowed for the drug to 
release, but even with no pre-incubation there was significant protection. This is 
important as the treatment is translated to in vivo models because the drug will be more 
effective if it plays a protective role immediately upon administration. 
The overall conclusion of the in vitro study with neuroblastoma cells was that 
there was a need for corroboration of the data obtained from a more relevant cell culture 
model. It is necessary to confirm this data in order to effectively translate this treatment 
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into an animal model for further evaluation. Thus, further in vitro analysis was to be 
performed in a primary neuronal cell model. 
A primary dorsal root ganglion culture was used to continue evaluation of the 
treatment. The dose dependent study confirmed the findings of the neuroblastoma model 
that the treatment is significantly protective against oxidative stress. The dose required 
for significance was consistent between the two cell culture models, but there was higher 
significance in the primary model, which should have more relevance to an in vivo study 
than the neuroblastoma model. This higher level of significance gives credence to the 
theory that the model should be effective in treating the secondary effects following 
spinal cord injury in vivo. 
The primary pre-treatment study saw a similar increase in significance over the 
neuroblastoma experiment. In this case the cells which were treated by nanoparticle 
delivered hormone were almost unaffected by the induced oxidative stress. This can be 
seen in that the viability was just below that of the positive control, which was not subject 
to the oxidative challenge. Again, significance was seen in all pre-treatment times which 
confirmed the data observed in the neuroblastoma model. The treatment window study 
showed that the treatment is significantly effective in the primary cell model even 15 
minutes after the secondary effects were induced. The combination of the pre-treatment 
and the treatment window study show a trend of increasing viability as more time for 
release is allowed. This is important because the therapeutic window for treatment is over 
several days following injury, so the high viability observed at 24 hours before the 
induction of injury conditions is still relevant. While it only takes an hour for extensive 
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cell death in the vitro conditions the time frame in vivo is much longer. This allows for a 
more effective treatment with neuroprotection for several days. 
Overall, the conclusions made from the in vitro study with neuroblastoma cells 
were confirmed in the primary cell culture. There was a protective effect exhibited in 
both cases, but the more clinically relevant primary model was more protected by the 
drug and saw a more significant improvement than those that were not treated. The pre-
treatment studies also illustrated that the primary cell model was more responsive to 
treatment with higher viability levels after treatment. Another consistent observation was 
that all time points for the pre-treatment study showed significant neuroprotection. This 
indicates an immediate therapeutic role being played by the nanoparticle treatment. 
7.2 Future Directions 
While there has been evidence of treatment efficacy shown herein, there is still 
much work to be done. First, more experiments remain to prove further efficacy of this 
treatment system. There could also be an expansion of the treatment to more disesase 
models. Combination of this treatment with other therapies to produce the most effective 
disease treatments is another future direction. Here we will outline some of the future 
work to continue development, modification, and studies to show efficacy of the 
developed controlled release formulation for 17β-estradiol therapy. 
 One of the first experiments which should be performed is an analysis of the 
estrogen concentration in cell culture medium. There was some question of release rate in 
cell culture medium due to a lower response to estrogens in low concentration than was 
expected. An ELISA which accurately measures serum 17β-estradiol can be used to 
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evaluate this release in vitro. This data can also be compared to the in vitro release 
described in this document, and to a potential future study which could examine drug 
concentration and release in vivo. Our collaborators at the Medical University of South 
Carolina will evaluate the release of estrogens in vitro in a cell culture using an estradiol 
ELISA kit. 
There are many applications of the method proposed here for the release profile 
determination of hydrophobic drugs. This could be especially useful if accelerated aging 
with the system is demonstrated as a potential application of the system. One path of 
future research examines this possibility and would explore the effect of increased 
temperature to accelerate the degradation of polymers and the release of drugs. With 
some polymeric drug delivery systems taking several months to release their load, an 
accelerated aging system would decrease the time necessary to analyze release. 
Another potential study would determine the ability of the nanoparticles to diffuse 
in the spinal cord tissue. This would be a useful experiment as the diffusion of these 
particles is helpful if it is only a small degree of diffusion, but could lead to problems if 
the diffusion is extensive. It is also important to show that the particles are not able to get 
into the circulation and be carried everywhere in the body. This study could be performed 
using fluorescently labeled nanoparticles administered in a small animal model through 
local administration while following fluorescence through in vivo monitoring. The 
monitoring could be performed using an IVIS Lumina XR in vivo imaging system.  
The ultimate goal for this study is to translate the formulation into a viable drug 
candidate that effectively treats spinal cord injury. To achieve this goal, there are several 
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steps to be taken. First, a few more characterization steps will be carried out to determine 
treatment dosing and administration time, some of which have already been mentioned.. 
These experiments will serve to confirm the experiments performed here. Our 
collaborators at MUSC will use an organotypic model using a sectioned rat spinal cord to 
determine the treatment efficacy in vitro with all the cells and matrix in its native 
arrangement. This study should lead to effective translation into an animal model to study 
the proposed drug. 
 A rat model will be used to analyze the drug’s efficacy. A spinal cord injury 
model using a defined weight dropped from a consistent height onto the exposed spinal 
cord will mimic the spinal cord injury and the treatment will be directly applied at the 
injury site. If the rat study is completed with success and improvements in motor 
functions are seen as well as other benchmark outcomes, then a small scale human trial 
will commence. The scale of the clinical trials will increase until FDA approval is 
achieved or if the drug proves to be unsafe or lack sufficient efficacy to continue. 
 Future work will also include further characterization of the particle make-up. The 
composition of the particles will be analyzed including the evaluation of the drug and 
polymeric components and their distribution in the particles. This is an important factor 
in determining how the body will respond to the therapeutic treatment. It also will add 
insight into the material which will aid in explaining and predicting the degradation and 
release profile, as well as the physiological response and biodistribution. 
Another area of research which could improve the therapeutic efficacy of the 
proposed system is the addition of another therapeutic drug to work in tandem with 17β-
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estradiol. As mentioned, there are many pathways which cause damage after SCI, and the 
solution may be in one drug that plays several therapeutic roles, or in a combination of 
drugs. Estrogens do function in several protective roles, but the addition of other drugs 
which can, for example, stimulate axonal regeneration would be advantageous. Other 
therapeutic drugs could also be explored. 
Also, the first several weeks after the injury could be treated by the proposed 
system, and then a biomaterial system with stem cells and cytokines to stimulate 
regeneration could be utilized. Such a system has been explored by the group led by Dr. 
Sakiyama-Elbert 
223, 224
. This work focuses on repairing the spinal cord using controlled 
release of chemical factors which stimulate growth and recovery 
225-227
 in combination 
with the seeding of new cells 
228, 229
 and the formulation of a structure which promotes 
ingrowth 
226, 230
. The combination of such therapies could be the most effective treatment 
to repair the damage caused by SCI. 
Another potential long-term application of this technology, if it sees success in 
this application, is in the treatment of other diseases. The PLGA nanoparticle loaded with 
estrogen for delivery could be potentially effective at treating other diseases. Estrogens 
are thought to be involved in the pathology of several diseases, especially those which are 
related to the nervous system. Parkinson’s disease, Alzheimer’s disease, and multiple 
sclerosis are diseases which estrogen may have therapeutic potential. If estrogen is shown 
to be involved in the biochemical pathways related to these diseases, then the 
neuroprotective role of estrogens could be useful for therapeutic application.  
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 For example, some experts believe that estrogens play a role in the development 
of Parkinson’s disease. This thought stems from the fact that many populations at risk for 
Parkinson’s have a low or lessened estrogenic production level 11. However, this 
hormonal involvement in the pathology of Parkinson’s disease is contested 11. If estrogen 
treatment of spinal cord injury proves to have a therapeutic effect, there are other 
potential paths for successful treatment of other diseases with limited side effects. 
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Appendix A: Abbreviations 
AFM – Atomic force microcopy 
BCNU -1,3-bis (2-chloroethyl)-1-
nitrosourea 
BSA – Bovine serum albumin 
CNS – Central nervous system 
DLS – Dynamic light scattering 
DMEM – Dulbecco’s Modified Eagles 
Medium 
DMSO – Dimtheyl sulfoxide 
DRG – Dorsal root ganglion 
EPR – Enhanced permeation and 
retention 
FDA – Food and Drug Administration of 
the United States government 
IVIVC – In vitro in vivo correlation 
MP – Methylprednisolone 
MTT - (3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide) 
NASCIS –National Acute Spinal Cord 
Injury Study 
NMDA – N-methyl-D-aspartic acid 
PBS – Phosphate buffered saline 
PEG – Poly (ethylene glycol) 
PEG-PLA – Poly (ethylene glycol 
(block)-co-polylactic acid (block)) 
PGA – Poly (glycolic acid) 
PLA – Poly (lactic acid) 
PLGA – Poly (lactic-co-glycolic acid) 
RES – Reticuloendothelial System 
ROS – Reactive Oxygen Species 
SCI – Spinal cord Inury 
SPARC - Secreted protein, acidic and 
rich in cysteine  
TEM – Transmission electron 
microscope
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Appendix B: AFM  Calibration and Supplemental Images 
 
Figure 31: Screenshot showing the consistent fit of the thermal graph and other 
details before AFM imaging was performed.  
 
 
Figure 32: AFM tune graph done before the readings on the nanoparticle size. 
TuneGraph
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Figure 33: Screenshot showing the details of the 20µM scan of the nanoparticles.  
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Figure 34: Evaluation of the size of the measured nanoparticles in a 3µM scan. 
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Figure 35: Height determination in the 3µM scan 
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Figure 36: Height analysis of the small residue on the substrate. The leading 
thought is that this is residue of PEG from once attached nanoparticles which 
were blown off or rolled to a new location.  
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Appendix C: DLS Supplemental Images 
 
Figure 37: DLS screenshot which shows a high number of particles centered around 
50 nm, but with a small group of larger particles. The effective diameter is much 
larger than the bars would indicate, but the value is affected more heavily by 
intensity than number (see next Figure)
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Figure 38: DLS image showing the high intensity of the larger particles. The laser 
scattering is much more intensified with the large particles (which are likely 
aggregates), and thus the effective diameter which program computes is weighted 
towards larger particles. 
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Figure 39: Correlation function of the reading on estrogen nanoparticles from the 
DLS. This correlation function fits the approximate shape appropriate for accurate 
reading function. 
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